{
    "items": "206",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Pill-Popping and the Next Pizza Slice",
            "url": "https://www.barrons.com/articles/pill-popping-and-the-next-pizza-slice-78672877",
            "time_published": "20230929T234000",
            "authors": [],
            "summary": "I'm an Eli Lilly and Novo Nordisk investor, and it's great to see how their GLP-1 weight-loss drugs can help to get one of our biggest problems worldwide under control.",
            "banner_image": "https://images.barrons.com/im-785422/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.076109,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.595343",
                    "ticker_sentiment_score": "0.111327",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of Structure Therapeutics Are Soaring on Friday",
            "url": "https://www.fool.com/investing/2023/09/29/why-shares-of-structure-therapeutics-are-soaring-o/",
            "time_published": "20230929T165023",
            "authors": [
                "Jim Halley"
            ],
            "summary": "The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.197045,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.059066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.319855",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.059066",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data",
            "url": "https://www.cnbc.com/2023/09/29/obesity-pill-data-boosts-structure-therapeutics-shares.html",
            "time_published": "20230929T160236",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107200974-1677600992263-gettyimages-1351638407-16.jpeg?v=1696003817&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.138186,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.234193",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.203829",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.144874",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment",
            "url": "https://www.marketwatch.com/story/as-merck-astrazeneca-and-other-drugmakers-sign-on-medicare-price-negotiations-face-critical-moment-9d85879f",
            "time_published": "20230929T142000",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.",
            "banner_image": "https://images.mktw.net/im-860220/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004787,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.138204",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "-0.006512",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Stocks to Focus on as Demand for Obesity Drugs Booms",
            "url": "https://www.zacks.com/stock/news/2157743/3-stocks-to-focus-on-as-demand-for-obesity-drugs-booms",
            "time_published": "20230929T133500",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.14477,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.169787",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.298437",
                    "ticker_sentiment_score": "0.153741",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.215702",
                    "ticker_sentiment_score": "0.061785",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A New Contender Enters The Weight-Loss Ring. Shares Rocket 66%.",
            "url": "https://www.investors.com/news/technology/biotech-stock-structure-catapults-as-it-takes-on-novo-lilly-in-weight-loss-drugs/",
            "time_published": "20230929T133400",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Biotech Stock Structure Catapults As It Takes On Novo, Lilly In ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/03/stock-pharmaceutical-6-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.038367,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.320974",
                    "ticker_sentiment_score": "0.267396",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.320974",
                    "ticker_sentiment_score": "-0.06137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.320974",
                    "ticker_sentiment_score": "0.267396",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million",
            "url": "https://www.cnbc.com/2023/09/29/obesity-diabetes-drug-ad-spending-hit-nearly-500-million-report.html",
            "time_published": "20230929T130012",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The data demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk's Ozempic and Wegovy.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277192-16903921852023-07-25t050143z_1484161984_rc2252ar8foe_rtrmadp_0_health-obesity-novo-nordisk-germany.jpeg?v=1695992412&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.042476,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today? - Structure Therapeutics  ( NASDAQ:GPCR ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/35001065/why-is-obesity-focused-structure-therapeutics-stock-trading-higher-today",
            "time_published": "20230929T125541",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Structure Therapeutics Inc GPCR released results from the Phase 1b multiple ascending dose ( MAD ) study of GSBR-1290 in healthy, overweight, or obese individuals. GSBR-1290 is an oral GLP-1 receptor agonist, similar to Novo Nordisk A/S's NVO popular drug, Wegovy ( semaglutide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/29/gpcr.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.097107,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.517168",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.277256",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/35000410/novo-nordisk-targets-high-demand-indian-market-for-its-popular-obesity-drugs-like-wegovy",
            "time_published": "20230929T123144",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Danish pharma giant Novo Nordisk A/s NVO has set its sights on India for the introduction of its breakthrough weight-loss drug Wegovy. The company aims for a 2026 launch in the country, contingent on securing regulatory approvals and ensuring an adequate supply to meet the anticipated demand.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/29/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.087216,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.70749",
                    "ticker_sentiment_score": "0.313117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats",
            "url": "https://www.business-standard.com/companies/news/novo-nordisk-india-head-eyes-2026-wegovy-launch-warns-against-copycats-123092900609_1.html",
            "time_published": "20230929T102014",
            "authors": [
                "Reuters"
            ],
            "summary": "BENGALURU ( Reuters ) -Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top company official told Reuters.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-06/20/full/1687266697-5888.jpg?im=FitAndFill=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.048147,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.247552",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NHGP",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.004061",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats",
            "url": "https://www.moneycontrol.com/news/business/novo-nordisk-india-head-eyes-2026-wegovy-launch-warns-against-copycats-11450031.html",
            "time_published": "20230929T055447",
            "authors": [],
            "summary": "The market opportunity for the drug is huge in the world's most populous country, where obesity rates are high especially among women. Illegal copycat versions of Wegovy are already being sold through online sites.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/08/1-Air-India-rebranding-.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.041,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.262548",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NHGP",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.004122",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-india-head-eyes-2026-wegovy-launch-warns-against-copycats-2023-09-29/",
            "time_published": "20230929T054400",
            "authors": [
                "Dhanya Skariachan"
            ],
            "summary": "BENGALURU, Sept 29 ( Reuters ) - Danish drugmaker Novo Nordisk ( NOVOb.CO ) aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top company official told Reuters.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/YHQYFMUWVVKUFFNKY5EYPXOAJI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.045746,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.233837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NHGP",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.004113",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/earnings/23/09/34984807/100-invested-in-this-stock-10-years-ago-would-be-worth-500-today",
            "time_published": "20230928T183026",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.79% on an annualized basis producing an average annual return of 18.54%. Currently, Novo Nordisk has a market capitalization of $409.70 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "NVO: 3 A-Rated Pharma Buys for October",
            "url": "https://stocknews.com/news/nvo-azn-nbix-3-a-rated-pharma-buys-for-october/",
            "time_published": "20230928T152729",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "The pharma industry is fueled by the introduction of generic medicines and a growing focus on the development of personalized medicines. Given the industry's steady growth prospects, investors could consider quality pharma stocks Neurocrine Biosciences, Inc. ( NBIX ) , Novo Nordisk A/S ( NVO ) , ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999696"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                }
            ],
            "overall_sentiment_score": 0.282619,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.264658",
                    "ticker_sentiment_score": "0.20527",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.357917",
                    "ticker_sentiment_score": "0.248698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NBIX",
                    "relevance_score": "0.232598",
                    "ticker_sentiment_score": "0.215165",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Anti-obesity Drug Market Is About to Get More Crowded",
            "url": "https://www.thedailyupside.com/industries/the-anti-obesity-drug-market-is-about-to-get-more-crowded/",
            "time_published": "20230928T143133",
            "authors": [
                "Griffin Kelly"
            ],
            "summary": "Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of...",
            "banner_image": null,
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.thedailyupside.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004809,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "-0.078458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "-0.02647",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "-0.109422",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "-0.078458",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma's big push for a new generation of obesity drugs",
            "url": "https://www.economist.com/business/2023/09/28/pharmas-big-push-for-a-new-generation-of-obesity-drugs",
            "time_published": "20230928T141008",
            "authors": [
                "The Economist"
            ],
            "summary": "F ago Novo Nordisk was a boring Danish drugmaker whose diabetes medications were reliably profitable. The only time the company made headlines was when it was caught up in complaints about the high cost of insulin. Then in 2021 a trial of its diabetes drug, Ozempic ( semaglutide ) , showed that ...",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230930_WBC753.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.150439,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.104455",
                    "ticker_sentiment_score": "0.06035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.05234",
                    "ticker_sentiment_score": "0.072857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.156123",
                    "ticker_sentiment_score": "0.100862",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.05234",
                    "ticker_sentiment_score": "0.072857",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34970749/despite-being-costly-ozempic-wegovy-prescriptions-surge-300-over-three-years",
            "time_published": "20230928T122231",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "An analytics firm Trilliant Health analysis revealed a significant surge in prescriptions for diabetes and obesity drugs like Ozempic and Wegovy during the last quarter of 2022. The quarterly prescriptions for these drugs have witnessed an astounding 300% increase from early 2020 to the end of 2022.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/28/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.222672,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.416844",
                    "ticker_sentiment_score": "0.067278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.519825",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-other-weight-loss-drugs-scrutinized-over-reports-suicidal-thoughts-2023-09-28/",
            "time_published": "20230928T100400",
            "authors": [
                "Chad Terhune",
                "Robin Respaut"
            ],
            "summary": "Dawn Heidlebaugh looks out of the window of her home in Findlay, Ohio, U.S., September 19, 2023. REUTERS/Megan Jelinger Acquire Licensing Rights Sept 28 ( Reuters ) - Dawn Heidlebaugh felt trapped in a disturbing pattern while taking Ozempic, the popular drug used to treat diabetes and obesity.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/M7Q6Y35K7BL7REEJ7DAPNYK5EE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.217514,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.018439",
                    "ticker_sentiment_score": "-0.210522",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036869",
                    "ticker_sentiment_score": "0.001989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.018439",
                    "ticker_sentiment_score": "0.054161",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk a Good Passive Income Stock?",
            "url": "https://www.fool.com/investing/2023/09/28/is-novo-nordisk-a-good-passive-income-stock/",
            "time_published": "20230928T092900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Producing cash isn't a problem for this pharma giant.",
            "banner_image": "https://media.ycharts.com/charts/580f2c330d45409339d42376a63fb5c1.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.3356,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.309377",
                    "ticker_sentiment_score": "0.30882",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.039679",
                    "ticker_sentiment_score": "0.127544",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA updates Ozempic label to acknowledge some users' reports of blocked intestines",
            "url": "https://www.cnn.com/2023/09/27/health/fda-ozempic-label/index.html",
            "time_published": "20230928T003300",
            "authors": [
                "Katherine Dillinger"
            ],
            "summary": "The US Food and Drug Administration has updated the label of the diabetes drug Ozempic to acknowledge reports of blocked intestines in some people using the medication. Ozempic and its sister drug, Wegovy, which is approved for weight loss, have recently soared in popularity.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230928082800-ozempic-injectable-drug-file.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.125251,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "-0.143271",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34953403/popular-weight-loss-drugs-ozempic-and-wegovy-alert-fda-adds-intestinal-blockage-warning",
            "time_published": "20230927T155250",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's NVO Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of blocked intestines following its use.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/warnings-image_by_openicons_from_pixabay.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.127534,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.433523",
                    "ticker_sentiment_score": "-0.118661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.660632",
                    "ticker_sentiment_score": "-0.181153",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years",
            "url": "https://www.cnbc.com/2023/09/27/ozempic-wegovy-drug-prescriptions-hit-9-million.html",
            "time_published": "20230927T142830",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The data confirms the rise in demand for GLP-1s, which have fueled a frenzy among Americans and on Wall Street for their ability to cause weight loss.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277197-16903924192023-03-29t000000z_263866917_rc2w30a1xtl3_rtrmadp_0_usa-health.jpeg?v=1695824910&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.012041,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.294682",
                    "ticker_sentiment_score": "-0.046064",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stories Wednesday, Sep 27: Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds - Alibaba Gr Holding  ( NYSE:BABA ) ",
            "url": "https://www.benzinga.com/news/23/09/34949379/apple-defends-its-19b-google-search-deal-hollywoods-writers-secure-credit-for-ai-training-chinas-amb",
            "time_published": "20230927T134747",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Alibaba Group Holding Limited BABA stock is trading higher Wednesday as the company's logistics arm Cainiao Smart Logistics Network Ltd filed for its Hong Kong initial public offering on Tuesday. The first-time share sale could fetch a minimum of $1 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/google_search_iphone.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.148277,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.111144",
                    "ticker_sentiment_score": "0.095986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.159668",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TGT",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.077628",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.184176",
                    "ticker_sentiment_score": "0.084378",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.111144",
                    "ticker_sentiment_score": "0.025411",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PARA",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.159668",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.07364",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRI",
                    "relevance_score": "0.111144",
                    "ticker_sentiment_score": "0.053298",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "-0.051384",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMG",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.273503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PAYX",
                    "relevance_score": "0.111144",
                    "ticker_sentiment_score": "0.070338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.147818",
                    "ticker_sentiment_score": "-0.038811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.147818",
                    "ticker_sentiment_score": "0.067619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.083661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients",
            "url": "https://www.cnn.com/2023/09/27/health/semaglutide-equitable-access/index.html",
            "time_published": "20230927T120000",
            "authors": [
                "Deidre McPhillips"
            ],
            "summary": "As prescriptions for Ozempic soar, the drug and others like it are still reaching only a fraction of the population who could benefit from taking them - and the limited supply is disproportionately reaching White patients.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230824132637-wegovy-2-4-pens.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.107853,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "-0.014634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05654",
                    "ticker_sentiment_score": "-0.07117",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen Could Get a Piece of the Obesity Market",
            "url": "https://www.wsj.com/finance/stocks/amgen-could-get-a-piece-of-the-obesity-market-5876ba75",
            "time_published": "20230927T100000",
            "authors": [
                "David Wainer"
            ],
            "summary": "Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.",
            "banner_image": "https://images.wsj.net/im-857279?width=700&height=525",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.246204,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.636698",
                    "ticker_sentiment_score": "0.470462",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Protein Engineering Market size to grow by USD 2.37 billion from 2022-2027| Agilent Technologies Inc., Amgen Inc ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/protein-engineering-market-size-to-grow-by-usd-2-37-billion-from-2022-2027-agilent-technologies-inc-amgen-inc-bio-rad-laboratories-inc-are-emerging-companies-in-the-market--technavio-301939213.html",
            "time_published": "20230926T234500",
            "authors": [],
            "summary": "Protein Engineering Market size to grow by USD 2.37 billion from 2022-2027| Agilent Technologies Inc., Amgen Inc ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.358109,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "A",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GNNSF",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRKR",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIO",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WAT",
                    "relevance_score": "0.138863",
                    "ticker_sentiment_score": "0.121471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DHR",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.06925",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Gains As Market Dips: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2155718/novo-nordisk-nvo-gains-as-market-dips-what-you-should-know",
            "time_published": "20230926T215018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Novo Nordisk (NVO) closed at $91.79, marking a +0.72% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default237.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.066626,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.551622",
                    "ticker_sentiment_score": "0.128077",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Magnificent Dividend Stocks to Buy Right Now",
            "url": "https://www.fool.com/investing/2023/09/26/2-magnificent-dividend-stocks-to-buy-right-now/",
            "time_published": "20230926T170000",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two expensive dividend stocks are worth the price of admission.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F748811%2Ftime-to-buy.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.356891,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.337037",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.257668",
                    "ticker_sentiment_score": "0.442075",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "EU regulator to discuss anaesthesia risk for weight-loss drugs",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-discuss-anaesthesia-risk-weight-loss-drugs-2023-09-26/",
            "time_published": "20230926T164400",
            "authors": [
                "Ludwig Burger"
            ],
            "summary": "The exterior of EMA, European Medicines Agency is seen in Amsterdam, Netherlands December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LPZOZ52XOBMCDLMFHQZI5YJIKI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.007199,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.063476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.026147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.063476",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO ) , Valo Ink Deal to Develop Heart Disease Drugs",
            "url": "https://www.zacks.com/stock/news/2155413/novo-nordisk-nvo-valo-ink-deal-to-develop-heart-disease-drugs",
            "time_published": "20230926T133600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.219776,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BTTX",
                    "relevance_score": "0.277118",
                    "ticker_sentiment_score": "0.050008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CORT",
                    "relevance_score": "0.16849",
                    "ticker_sentiment_score": "0.120199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.16849",
                    "ticker_sentiment_score": "0.089915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.564693",
                    "ticker_sentiment_score": "0.388379",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Will Insulet  ( PODD )  Stock Recover To Its Pre-Inflation Shock Highs Of $300?",
            "url": "https://www.forbes.com/sites/greatspeculations/2023/09/26/will-insulet-podd-stock-recover-to-its-pre-inflation-shock-highs-of-300/",
            "time_published": "20230926T130052",
            "authors": [
                "Trefis Team"
            ],
            "summary": "Returning to the pre-inflation shock level of $318 means that PODD stock will have to gain more than 100% from here.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65125ecb399c931d76759e52/0x0.jpg?format=jpg&width=1200",
            "source": "Forbes",
            "category_within_source": "Markets",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": -0.031878,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "-0.064992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.68701",
                    "ticker_sentiment_score": "0.015369",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/novo-nordisk-and-evotec-collaborate-to-launch-lab-en-a-translational-drug-discovery-accelerator-to-address-innovation-gap-in-cardiometabolic-diseases-301938759.html",
            "time_published": "20230926T113000",
            "authors": [],
            "summary": "Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.252745,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.046633",
                    "ticker_sentiment_score": "0.054894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.046633",
                    "ticker_sentiment_score": "0.054894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.191273",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EVO",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.353902",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "The Surprise That Prompted This Stock To Dump 52% Over Two Days",
            "url": "https://www.investors.com/news/technology/morf-stock-collapses-over-two-days-as-takeda-rivalry-slams-ulcerative-colitis-drug/",
            "time_published": "20230925T164500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "MORF Stock Collapses 52% Over Two Days As Takeda Rivalry ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/Stock-drugMedicine-03-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.048503,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MORF",
                    "relevance_score": "0.836337",
                    "ticker_sentiment_score": "0.037203",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "-0.200877",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "-0.201941",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748846/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20230925T150700",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 25 September 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.14916,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.04325",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.04325",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.24668",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Valo to research cardiometabolic treatments",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-valo-research-cardiometabolic-treatments-2023-09-25/",
            "time_published": "20230925T124900",
            "authors": [
                "Reuters"
            ],
            "summary": "Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/HKTER5Y4FBO3BAFYYIBBMNXRBI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.06451,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.745397",
                    "ticker_sentiment_score": "0.144965",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748601/0/en/Valo-Health-and-Novo-Nordisk-to-collaborate-to-discover-and-develop-novel-treatments-for-cardiometabolic-diseases-using-human-data-and-artificial-intelligence.html",
            "time_published": "20230925T120000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Collaboration will apply Valo's Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.26086,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.054727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.054727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.415927",
                    "ticker_sentiment_score": "0.27411",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus",
            "url": "https://www.zacks.com/stock/news/2154739/beat-the-market-like-zacks-elementis-novo-nordisk-amgen-in-focus",
            "time_published": "20230925T115000",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                }
            ],
            "overall_sentiment_score": 0.163831,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BR",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.002005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.132272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCC",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.150343",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PAYX",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.060206",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMSOF",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.168547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.002005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.060206",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSCI",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.106185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SABR",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.173936",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EMNSF",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.183194",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.09893",
                    "ticker_sentiment_score": "0.11237",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FMC Corporation names Jacqueline Scanlan as new chief human resources officer - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/fmc-corporation-names-jacqueline-scanlan-as-new-chief-human-resources-officer-301936469.html",
            "time_published": "20230925T113000",
            "authors": [],
            "summary": "FMC Corporation names Jacqueline Scanlan as new chief human resources officer PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.139898,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AXTA",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.018081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPB",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.018081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HAE",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.018081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.018081",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...",
            "url": "https://www.fool.com/investing/2023/09/25/which-high-profile-stock-split-stock-is-cheapest/",
            "time_published": "20230925T092100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F748247%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.692272"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.26852,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.074576",
                    "ticker_sentiment_score": "0.130831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.13785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.074576",
                    "ticker_sentiment_score": "0.130831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.074576",
                    "ticker_sentiment_score": "0.130831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.13785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.065077",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "USEG",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.13785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.360229",
                    "ticker_sentiment_score": "0.22883",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.13785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.074576",
                    "ticker_sentiment_score": "0.130831",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Paramount Global and Netflix stock boosted by possible end to writer's strike as Nike shares slip on downgrade",
            "url": "https://www.marketwatch.com/story/paramount-global-and-netflix-stock-boosted-by-possible-end-to-writers-strike-as-nike-shares-slip-on-downgrade-a44ea4ba",
            "time_published": "20230925T090700",
            "authors": [
                "MarketWatch"
            ],
            "summary": "Paramount Global, Netflix, Foot Locker and Nike were stocks in the spotlight.",
            "banner_image": "https://images.mktw.net/im-857259/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.077644,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.008729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.595343",
                    "ticker_sentiment_score": "0.490681",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PARA",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.008729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FL",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "-0.222524",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.257192",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.409693",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "-0.008893",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URBN",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "-0.222524",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.",
            "url": "https://markets.businessinsider.com/news/stocks/ozempic-wegovy-glp1-weight-loss-drugs-stock-market-winners-losers-2023-9",
            "time_published": "20230924T123000",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Weight Loss Drugs Like Ozempic Could Have Surprising Stock Market Effects - Markets Insider ...",
            "banner_image": "https://i.insider.com/650dd35323ce9d00190894e9?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.002433,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MO",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.048352",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNDM",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "0.10225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "0.203966",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "0.05848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.006167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "0.154644",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLNT",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.087154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMD",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.103818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.005848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "0.172697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.005848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "YUM",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.005848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "-0.005848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "-0.01019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A fund manager at a $250 billion firm that aims to capture megatrends shares the top 10 stocks pulled from its 12 strategies",
            "url": "https://www.businessinsider.com/top-stocks-set-to-gain-from-global-megatrends-fund-manager-2023-9",
            "time_published": "20230923T090100",
            "authors": [
                "Laila Maidan"
            ],
            "summary": "Top 10 Stocks Set to Gain From Global Megatrends: Fund Manager - Business Insider ...",
            "banner_image": "https://i.insider.com/650e00bbe453d50019f7ecf1?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.321271,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KLAC",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.08414",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.129746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRBZF",
                    "relevance_score": "0.039224",
                    "ticker_sentiment_score": "0.221503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.129746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "-0.110586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RSG",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "-0.004156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.194259",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.30089",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.117295",
                    "ticker_sentiment_score": "0.147665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROP",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.129746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.230088",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.20142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SBGSF",
                    "relevance_score": "0.039224",
                    "ticker_sentiment_score": "0.361151",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.129746",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs - WW International  ( NASDAQ:WW ) , Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34832242/ww-international-shares-jump-on-bcbs-michigans-revised-authorization-for-wegovy-other-weight-loss",
            "time_published": "20230922T202554",
            "authors": [
                "AJ Fabino"
            ],
            "summary": "Shares of WW International Inc WW spiked as much as 15% on Friday after Blue Cross Blue Shield of Michigan and Blue Care Network announced changes to the prior authorization coverage criteria for certain brand-name weight loss medications.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/ww_international_shutter2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.185912,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "WW",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.156135",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.039876",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.029235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.065377",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "PFE: Pfizer Inc.  ( PFE )  - Buy or Hold Analysis on This Pharma Stock",
            "url": "https://stocknews.com/news/pfe-nvs-nvo-snphy-pfizer-inc-pfe-buy-or-hold-analysis-on-this/",
            "time_published": "20230922T165719",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "Pfizer Inc. ( PFE ) has reported a decline in revenue this year, as sales of its COVID-related products have started to fall.",
            "banner_image": "https://stocknews.com/wp-content/uploads/2016/11/pfizer-world-hq.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998682"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.140094,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.053749",
                    "ticker_sentiment_score": "0.150745",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNPHF",
                    "relevance_score": "0.02689",
                    "ticker_sentiment_score": "0.140184",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053749",
                    "ticker_sentiment_score": "0.150745",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.520971",
                    "ticker_sentiment_score": "0.127195",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Where Will Novo Nordisk Stock Be in 5 Years?",
            "url": "https://www.fool.com/investing/2023/09/22/where-will-novo-nordisk-stock-be-in-5-years/",
            "time_published": "20230922T135300",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.216786,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.449503",
                    "ticker_sentiment_score": "0.259834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AstraZeneca Surges After Breast Cancer Drug Tops Chemo",
            "url": "https://www.investors.com/news/technology/azn-stock-surges-after-breast-cancer-drug-tops-chemo/",
            "time_published": "20230922T134900",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "AZN Stock Surges After Breast Cancer Drug Tops Chemo Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-AstraZenecaFlags-01-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": -0.154543,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "-0.155649",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.140076",
                    "ticker_sentiment_score": "-0.375818",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "-0.155649",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "-0.201114",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.140076",
                    "ticker_sentiment_score": "-0.238699",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Pfizer Takeover",
            "url": "https://www.investors.com/news/technology/sgen-stock-pops-after-scoring-a-must-win-for-its-pfizer-takeover/",
            "time_published": "20230922T133000",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Pfizer ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-Seagen-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.066484,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "-0.374741",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.780579",
                    "ticker_sentiment_score": "-0.213336",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "-0.237966",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.011197",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S Upgraded to Strong Buy Rating by StockNews.com Analysts",
            "url": "https://www.claytoncountyregister.com/news2/novo-nordisk-a-s-nysenvo-raised-to-strong-buy-at-stocknews-com/477512/",
            "time_published": "20230922T082723",
            "authors": [
                "Barret Loux"
            ],
            "summary": "Novo Nordisk A/S Upgraded to Strong Buy Rating by StockNews ... Clayton County Register ...",
            "banner_image": "https://www.claytoncountyregister.com/wp-content/uploads/2023/07/mfrack_realistic_photo_of_nasdaq_stock_exchange_83c5cbdd-39fa-4663-b284-8db6892ab8d0.jpeg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.claytoncountyregister.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.196513,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.699089",
                    "ticker_sentiment_score": "0.309825",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S Upgraded to Strong-Buy Rating by Analysts at StockNews.com",
            "url": "https://www.claytoncountyregister.com/news2/novo-nordisk-a-s-nysenvo-raised-to-strong-buy-at-stocknews-com-2/477526/",
            "time_published": "20230922T075327",
            "authors": [
                "Jorge Diaz"
            ],
            "summary": "Novo Nordisk A/S Upgraded to Strong-Buy Rating by Analysts at ... Clayton County Register ...",
            "banner_image": "https://www.claytoncountyregister.com/wp-content/uploads/2023/07/mfrack_realistic_photo_of_nasdaq_market_3277c1c3-7850-4cf7-8ea0-5a807c001147.jpeg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.claytoncountyregister.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.186994,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.771935",
                    "ticker_sentiment_score": "0.306437",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S  ( NYSE:NVO )  Raised to Strong-Buy at StockNews.com",
            "url": "https://www.defenseworld.net/2023/09/22/novo-nordisk-a-s-nysenvo-raised-to-strong-buy-at-stocknews-com.html",
            "time_published": "20230922T071642",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "Novo Nordisk A/S ( NYSE:NVO ) Raised to Strong-Buy at StockNews ... Defense World ...",
            "banner_image": "https://www.marketbeat.com/logos/novo-nordisk-logo.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.319747,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.262179",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SEIC",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.262179",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.130455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.815149",
                    "ticker_sentiment_score": "0.513428",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.",
            "url": "https://markets.businessinsider.com/news/stocks/gurnet-point-capital-and-novo-holdings-a-s-complete-acquisition-of-paratek-pharmaceuticals-inc-1032646807",
            "time_published": "20230922T015144",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "CAMBRIDGE, Mass., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Gurnet Point Capital ( \"Gurnet Point\" ) and Novo Holdings A/S ( \"Novo Holdings\" ) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ( \"Paratek\" or the \"Company\" ) ( Nasdaq: PRTK ) , a commercial-stage ...",
            "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=ODkyNjQwMCM1ODI1NTExIzIwMjg2ODQ=",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.27074,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZLAB",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "0.128622",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTK",
                    "relevance_score": "0.142005",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "0.055205",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234458",
                    "ticker_sentiment_score": "0.276656",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "-0.001989",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Was Tumbling on Thursday",
            "url": "https://www.fool.com/investing/2023/09/21/why-novo-nordisk-stock-was-tumbling-on-thursday/",
            "time_published": "20230921T195635",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A downbeat analyst take resonated with investors.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.019472,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.003353",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why This Former Highflier Just Crashed 41% To A Decade-Low",
            "url": "https://www.investors.com/news/technology/tvtx-stock-crashes-after-kidney-drug-fails-to-pass-muster-in-a-confirmatory-study/",
            "time_published": "20230921T165400",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "TVTX Stock Crashes After Kidney Drug Fails To Pass Muster In A ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-biotechLab-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.114192,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "-0.207086",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "-0.199529",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Holdings, Gurnet Point close $462 mln acquisition of Paratek Pharmaceuticals",
            "url": "https://www.reuters.com/markets/deals/novo-holdings-closes-462-mln-acquisition-paratek-pharmaceuticals-2023-09-21/",
            "time_published": "20230921T163302",
            "authors": [
                "Reuters"
            ],
            "summary": "COPENHAGEN, Sept 21 ( Reuters ) - Novo Holdings, controlling shareholder in drugmaker Novo Nordisk ( NOVOb.CO ) , and Gurnet Point Capital on Thursday closed their acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal worth $462 million, Novo Holdings said.",
            "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=157",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.060659,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PRTK",
                    "relevance_score": "0.644033",
                    "ticker_sentiment_score": "-0.121431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.644033",
                    "ticker_sentiment_score": "0.222781",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Coca-Cola Short Seller Says Dominance Fizzles In Face Of Bubbly Upstarts, Weight Loss Drugs - Celsius Holdings  ( NASDAQ:CELH ) , Coca-Cola  ( NYSE:KO ) , Novo Nordisk  ( NYSE:NVO ) , Berkshire Hathaway Inc. Common Stock  ( NYSE:BRK/A ) ",
            "url": "https://www.benzinga.com/news/large-cap/23/09/34799144/coca-cola-short-seller-says-dominance-fizzles-in-face-of-bubbly-upstarts-weight-loss-drugs",
            "time_published": "20230921T161854",
            "authors": [
                "AJ Fabino"
            ],
            "summary": "Coca-Cola Co KO is recognized globally as a beverage giant with roughly 200 brands under its name and products consumed over two billion times each day.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Coke.Fizzle.Shutterstock.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.099788,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.191699",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.670181",
                    "ticker_sentiment_score": "0.264588",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.034044",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.061871",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Unusual Options Activity For September 21 - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/09/34796560/novo-nordisk-unusual-options-activity-for-september-21",
            "time_published": "20230921T153157",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bearish stance on Novo Nordisk NVO. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.167131,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.696714",
                    "ticker_sentiment_score": "0.164121",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Stock Market Sees More Pain; FedEx Stock Soars On Earnings",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-sees-more-pain-fedex-stock-soars-on-earnings/",
            "time_published": "20230921T144700",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Sees More Pain. FedEx Stock Soars On Earnings Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-jobsearch-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.016971,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KBH",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "-0.073631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "0.12049",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.028313",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "0.190702",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "-0.234547",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "0.136735",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPLK",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.083718",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "-0.067265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "-0.008014",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drugs Will Make Billions. But They Could Break the Healthcare System in the Process.",
            "url": "https://www.barrons.com/articles/wegovy-ozempic-obesity-drugs-healthcare-system-20307eea",
            "time_published": "20230921T131703",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "How Wegovy and Weight-Loss Drugs Could Break the Healthcare ... ...",
            "banner_image": "https://images.barrons.com/im-10315285?width=940&height=626",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.039595,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "-0.074275",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. - Paratek Pharmaceuticals  ( NASDAQ:PRTK ) ",
            "url": "https://www.benzinga.com/pressreleases/23/09/g34791170/gurnet-point-capital-and-novo-holdings-as-complete-acquisition-of-paratek-pharmaceuticals-inc",
            "time_published": "20230921T125857",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "CAMBRIDGE, Mass., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Gurnet Point Capital ( \"Gurnet Point\" ) and Novo Holdings A/S ( \"Novo Holdings\" ) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ( \"Paratek\" or the \"Company\" ) PRTK, a commercial-stage biopharmaceutical ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.252535,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZLAB",
                    "relevance_score": "0.046006",
                    "ticker_sentiment_score": "0.117351",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTK",
                    "relevance_score": "0.137409",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.046006",
                    "ticker_sentiment_score": "0.055006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.269959",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.046006",
                    "ticker_sentiment_score": "0.039724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747312/33636/en/Gurnet-Point-Capital-and-Novo-Holdings-A-S-Complete-Acquisition-of-Paratek-Pharmaceuticals-Inc.html",
            "time_published": "20230921T125800",
            "authors": [
                "Paratek Pharmaceuticals"
            ],
            "summary": "CAMBRIDGE, Mass., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Gurnet Point Capital ( \"Gurnet Point\" ) and Novo Holdings A/S ( \"Novo Holdings\" ) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ( \"Paratek\" or the \"Company\" ) ( Nasdaq: PRTK ) , a commercial-stage ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/004d3d9f-8cdc-44bc-82de-0acba4447377",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.27074,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZLAB",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "0.128622",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTK",
                    "relevance_score": "0.142005",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "0.055205",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234458",
                    "ticker_sentiment_score": "0.276656",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.047559",
                    "ticker_sentiment_score": "-0.001989",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Finds 'Objectionable' Bacteria In Diabetes Pill Batches: FDA",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-fda-inspection-turns-up-objectionable-bacteria-in-key-plant/",
            "time_published": "20230921T120000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk Stock: FDA Inspection Turns Up 'Objectionable ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/08/Stock-wegovy-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.061681,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.554916",
                    "ticker_sentiment_score": "0.147543",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medtech Makers Are Real Losers From Obesity Drugs",
            "url": "https://www.barrons.com/articles/weight-loss-drugs-obesity-eli-lilly-novo-nordisk-bcd3dd6e",
            "time_published": "20230921T050000",
            "authors": [
                "Bill Alpert"
            ],
            "summary": "Weight-Loss Drugs Are Bad News for Companies That Treat Obesity ... ...",
            "banner_image": "https://images.barrons.com/im-06751388?width=700&height=466",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.119443,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "INSP",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.161174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TNDM",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.161174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.428457",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.428457",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.161174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RMD",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.161174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.161174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.586747",
                    "ticker_sentiment_score": "0.049711",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drugs Will Make Billions. But They Could Break the Healthcare System in the Process.",
            "url": "https://www.barrons.com/articles/obesity-drugs-healthcare-system-20307eea",
            "time_published": "20230921T050000",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "Obesity Drugs Will Make Billions. But They Could Break the ... ...",
            "banner_image": "https://images.barrons.com/im-10315285?width=940&height=626",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.066562,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "-0.023921",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Gains As Market Dips: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2153366/novo-nordisk-nvo-gains-as-market-dips-what-you-should-know",
            "time_published": "20230920T215018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) closed the most recent trading day at $94.73, moving +1.29% from the previous trading session.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default323.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.166637,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.540358",
                    "ticker_sentiment_score": "0.182337",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Edged Higher Today",
            "url": "https://www.fool.com/investing/2023/09/20/why-novo-nordisk-stock-edged-higher-today/",
            "time_published": "20230920T210825",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The good news outweighed the bad for the hot drug developer on Hump Day.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.18612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.220341",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.713572",
                    "ticker_sentiment_score": "0.255944",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity",
            "url": "https://www.globenewswire.com/news-release/2023/09/20/2746821/0/en/Novo-Nordisk-and-UNICEF-to-extend-joint-initiative-to-prevent-global-childhood-obesity.html",
            "time_published": "20230920T185800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "New York and Bagsværd, 20 September 2023 - Novo Nordisk and UNICEF today announced an extension of their long-term partnership to help prevent global childhood overweight and obesity - a public health crisis that affects millions of children worldwide.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.176975,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.389636",
                    "ticker_sentiment_score": "0.264461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Drug Giant Hits Profit Zone Amid Enthusiasm For Weight Loss Drug",
            "url": "https://www.investors.com/stock-lists/stock-spotlight/eli-lilly-stock-hits-profit-zone-amid-enthusiasm-for-weight-loss-drug/",
            "time_published": "20230920T185300",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Drugmaker Eli Lilly ( LLY ) hit a profit zone amid a string of torrid gains, as Wall Street remains enthusiastic over the prospects for weight-loss drugs. Eli Lilly stock is a member of IBD's Stock Spotlight list. Eli Lilly is set to rival Novo Nordisk ( NVO ) , the current leader in obesity ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/stock-Eli-Lilly-02-Shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                }
            ],
            "overall_sentiment_score": 0.321887,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.025076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.673811",
                    "ticker_sentiment_score": "0.5238",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "-0.034237",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  Stock Is Trading Higher Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34763042/ypsomed-to-supply-autoinjectors-to-novo-nordisk-under-long-term-agreement",
            "time_published": "20230920T143210",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Swiss medical technology company Ypsomed YPHDF announced a long-term supply deal with Novo Nordisk A/S NVO for autoinjectors. Novo has been unable to keep pace with demand for Wegovy, which uses autoinjectors.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/20/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.153265,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.758753",
                    "ticker_sentiment_score": "0.460853",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ginkgo Bioworks is Teaming Up With Alphabet For AI, But Does That Make It a Buy?",
            "url": "https://www.fool.com/investing/2023/09/20/ginkgo-bioworks-is-teaming-up-with-alphabet-for-ai/",
            "time_published": "20230920T135300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The move is unsurprising, but it will be positive for shareholders.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.227962,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.09215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "0.077759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.09215",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs",
            "url": "https://www.benzinga.com/pressreleases/23/09/g34762828/onkure-therapeutics-appoints-ann-howell-pharm-d-as-vice-president-of-regulatory-affairs",
            "time_published": "20230920T134152",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "BOULDER, Colo., Sept. 20, 2023 ( GLOBE NEWSWIRE ) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.25839,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.103191",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGIOF",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.103191",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk  ( NVO )  a Buy as Wall Street Analysts Look Optimistic?",
            "url": "https://www.zacks.com/stock/news/2153053/is-novo-nordisk-nvo-a-buy-as-wall-street-analysts-look-optimistic",
            "time_published": "20230920T133006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NVO_09202023.png",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.256594,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.357783",
                    "ticker_sentiment_score": "0.11473",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Cracks Down on Counterfeit Mounjaro Weight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34757757/eli-lilly-cracks-down-on-counterfeit-mounjaro-weight-loss-and-diabetes-drugs-sues-lawsuit-against",
            "time_published": "20230920T131854",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co LLY has taken legal action against ten entities in the U.S., including medical spas, wellness centers, and compounding pharmacies, alleging that they have been selling unauthorized, less expensive versions of its diabetes drug, Mounjaro ( tirzepatide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/20/mounjaro-medication-for-weight-loss.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.036823,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.60326",
                    "ticker_sentiment_score": "0.104015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.265378",
                    "ticker_sentiment_score": "-0.150153",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly Cracks Down on Counterfeit Mounjaro Wight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34757757/eli-lilly-cracks-down-on-counterfeit-mounjaro-wight-loss-and-diabetes-drugs-sues-lawsuit-against-",
            "time_published": "20230920T131854",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co LLY has taken legal action against ten entities in the U.S., including medical spas, wellness centers, and compounding pharmacies, alleging that they have been selling unauthorized, less expensive versions of its diabetes drug, Mounjaro ( tirzepatide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/20/mounjaro-medication-for-weight-loss.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.036823,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.60326",
                    "ticker_sentiment_score": "0.104015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.265378",
                    "ticker_sentiment_score": "-0.150153",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Denmark's Novo Nordisk and South Africa's Aspen sign a deal to produce insulin for African patients",
            "url": "https://apnews.com/article/south-africa-diabetes-insulin-96aa008ee463abc64fc2c85ac8da3052",
            "time_published": "20230920T094600",
            "authors": [
                "GERALD IMRAY"
            ],
            "summary": "CAPE TOWN, South Africa ( AP ) - Danish pharmaceutical company Novo Nordisk signed a deal with South Africa's Aspen Pharmacare to produce human insulin for diabetes patients in Africa, where there is a dire need for the life-saving treatment.",
            "banner_image": "https://dims.apnews.com/dims4/default/cd5adee/2147483647/strip/true/crop/4500x2997+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F8b%2F23%2Fda5d0b5a379c4fa0ecc4c65c3a7e%2Fe73e830d628643dd9deb610757b3f308",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.04264,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APNHF",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "-0.090265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.357293",
                    "ticker_sentiment_score": "0.015025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ypsomed signs autoinjector supply deal with Novo Nordisk",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/ypsomed-signs-autoinjector-supply-deal-with-novo-nordisk-2023-09-20/",
            "time_published": "20230920T072014",
            "authors": [
                "Reuters"
            ],
            "summary": "Ypsomed signs autoinjector supply deal with Novo ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/44OKLS6PLNPBZO3I3AAZ2PIMCE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.104046,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.627119",
                    "ticker_sentiment_score": "0.129081",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug",
            "url": "https://www.cnbc.com/2023/09/19/eli-lilly-sues-clinics-allegedly-selling-knockoff-versions-of-mounjaro.html",
            "time_published": "20230919T203305",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The lawsuits come as Eli Lilly grapples with a shortage of Mounjaro in the U.S. due to skyrocketing demand.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277199-16903924192023-03-29t000000z_926919308_rc2w30aq63my_rtrmadp_0_usa-health.jpeg?v=1695155585&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.125852,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "-0.150934",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "NVO: 3 Biotechs with Massive Growth Potential",
            "url": "https://stocknews.com/news/cort-regn-3-biotechs-with-massive-growth-potential/",
            "time_published": "20230919T195854",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "Question: How do you know an election is coming up in the United States? Answer: Politicians begin attacking biotech and pharmaceutical companies in the press. And why is that…because biotech and pharmaceutical companies appear to make \"outsized\" profits, and are therefore an easy target to ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.068061,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CORT",
                    "relevance_score": "0.26928",
                    "ticker_sentiment_score": "-0.006233",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.353688",
                    "ticker_sentiment_score": "0.049049",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Maker of diabetes drug Mounjaro takes legal action against compounders, spas and wellness centers",
            "url": "https://www.cnn.com/2023/09/19/health/eli-lilly-mounjaro-compound-lawsuit/index.html",
            "time_published": "20230919T190100",
            "authors": [
                "Amanda Musa"
            ],
            "summary": "Pharmaceutical company Eli Lilly has filed several lawsuits against certain US medical spas, wellness centers and compounding pharmacies in an attempt to stop them from \"the unlawful marketing and sale of non-FDA approved compounded products\" which the company says they're \"fraudulently ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/211222102206-weight-scale-doctors-office-stock.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.068164,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "-0.041833",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.073546",
                    "ticker_sentiment_score": "-0.054809",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/news/23/09/34730567/amazon-poaches-microsofts-product-chief-google-and-dod-team-up-for-ai-powered-microscope-to-identify",
            "time_published": "20230919T140151",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "After Microsoft Corp MSFT Chief Product Officer Panos Panay confirmed that he is leaving the software giant, a report said he is shifting base to Amazon Inc AMZN. Panay said in a post on X, formerly Twitter, \"After 19 incredible years at Microsoft, I've decided to turn the page and write the next ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/19/amazon_prime_rewards_card_32861518627.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.045478,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.45283",
                    "ticker_sentiment_score": "0.130859",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "-0.227221",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BGNE",
                    "relevance_score": "0.119631",
                    "ticker_sentiment_score": "-0.015196",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APNHF",
                    "relevance_score": "0.040011",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RKLB",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "-0.235829",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "-0.170158",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BP",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.078227",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.311829",
                    "ticker_sentiment_score": "0.119042",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGM",
                    "relevance_score": "0.119631",
                    "ticker_sentiment_score": "0.130667",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.119631",
                    "ticker_sentiment_score": "-0.019224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "-0.01346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGIOF",
                    "relevance_score": "0.040011",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Partners With South Africa-Based Aspen To Supply Insulin For African Countries - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34728652/novo-nordisk-partners-with-south-africa-based-aspen-to-supply-insulin-for-african-countries",
            "time_published": "20230919T132426",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO announced a new partnership with Aspen Pharmacare to establish human insulin production in South Africa. Aspen Pharmacare will manufacture human insulin in South Africa, specifically for export to African nations, through a cost-effective government tender system.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/19/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.130713,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APNHF",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.202211",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.397098",
                    "ticker_sentiment_score": "0.161305",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk contracts South Africa's Aspen to produce insulin for African nations",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-contracts-south-africas-aspen-produce-insulin-african-nations-2023-09-19/",
            "time_published": "20230919T090400",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "[1/2] Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/HKTER5Y4FBO3BAFYYIBBMNXRBI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.145607,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APNHF",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.11147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.107084",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk shares fall after media report on quality lapses at US plant",
            "url": "https://www.foxbusiness.com/markets/novo-nordisk-shares-fall-media-report-quality-lapses-us-plant",
            "time_published": "20230918T215943",
            "authors": [
                "Reuters"
            ],
            "summary": "Novo Nordisk's shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group's Clayton, North Carolina plant, citing sources. Reuters was not immediately able to authenticate the report.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/d5091cf1-50af-4727-bf1f-30a09cb7d446/19ca501c-b034-4129-a7e3-6a2ebc09d630/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004746,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "-0.081673",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Dipped Today",
            "url": "https://www.fool.com/investing/2023/09/18/why-novo-nordisk-stock-dipped-today/",
            "time_published": "20230918T212524",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "Popularity has its downsides.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.073225,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.751437",
                    "ticker_sentiment_score": "-0.066564",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Wary As It Waits For The Fed; New Arm IPO Sinks",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-wary-as-it-waits-for-the-fed-new-arm-ipo-sinks/",
            "time_published": "20230918T145000",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Stock Market Wary As It Waits For The Fed. New Arm IPO Sinks Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-Federal-Reserve-fall-01-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.111886,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AYX",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.143673",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.039251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.126092",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "-0.09228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.171688",
                    "ticker_sentiment_score": "0.034944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.250657",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CLX",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "-0.154341",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Top Stories Monday, Sep. 18: Single Bitcoin In 2021 Was Enough To Purchase A Tesla Model Y, Softbank Explores Investing In OpenAI, Ford Faces UAW Strike In US, Canada - Apple  ( NASDAQ:AAPL ) ",
            "url": "https://www.benzinga.com/markets/cryptocurrency/23/09/34692109/single-bitcoin-in-2021-was-enough-to-purchase-a-tesla-model-y-softbank-explores-investing-",
            "time_published": "20230918T142627",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In November 2021, when Bitcoin ( BTC/USD ) reached its all-time high of $67,617.02, the most valuable purchase that could have been made with a single BTC was the 2021 Tesla TSLA Model Y, priced at $62,190.00.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/18/bitcoin-2008262_1920.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.139462,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.124744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.38588",
                    "ticker_sentiment_score": "0.273651",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.199074",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "-0.041564",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.237745",
                    "ticker_sentiment_score": "-0.001841",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "-0.005166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.091388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFTBF",
                    "relevance_score": "0.159834",
                    "ticker_sentiment_score": "0.142601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.237745",
                    "ticker_sentiment_score": "0.290986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:DOGE",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.235993",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Dives After FDA Reportedly Turns Up 'Objectionable' Conditions At A Plant",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-skids-as-report-finds-objectionable-conditions-at-wegovy-plant/",
            "time_published": "20230918T141100",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk Stock Skids As Report Finds 'Objectionable ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.042874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.493442",
                    "ticker_sentiment_score": "-0.003188",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  Shares Are Falling Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34689054/quality-control-issues-at-novo-nordisks-clayton-plant-key-site-for-weight-loss-diabetes-drug-prod",
            "time_published": "20230918T135052",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The FDA has reportedly issued a report detailing quality control lapses at Novo Nordisk A/S's NVO Clayton, North Carolina plant. Clayton is a major site for the company's production of its active pharmaceutical ingredients, including semaglutide, which is used in its hugely popular weight-loss ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/18/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.145042,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.651499",
                    "ticker_sentiment_score": "0.30152",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?",
            "url": "https://www.forbes.com/sites/greatspeculations/2023/09/18/will-dexcom-stock-recover-to-its-pre-inflation-shock-highs-of-160/",
            "time_published": "20230918T130000",
            "authors": [
                "Trefis Team"
            ],
            "summary": "The notable increase in DexCom's revenues over recent quarters has also contributed to the stock recovery.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6507c744660465a285935f6b/0x0.jpg?format=jpg&width=1200",
            "source": "Forbes",
            "category_within_source": "Markets",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": -0.082601,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.712997",
                    "ticker_sentiment_score": "-0.104672",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "-0.136197",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus",
            "url": "https://www.zacks.com/stock/news/2151789/beat-the-market-the-zacks-way-automatic-data-processing-caseys-paysafe-in-focus",
            "time_published": "20230918T120200",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/1383.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.164045,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ESRT",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.252698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.101106",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRM",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.138195",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WWD",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.236342",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096932",
                    "ticker_sentiment_score": "0.106473",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSFE",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.236342",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CASY",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.062045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.061155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.061155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUBB",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.132178",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk hires private U.S. firm to handle some Wegovy pen assembly -source",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-hires-private-us-firm-handle-some-wegovy-pen-assembly-source-2023-09-18/",
            "time_published": "20230918T115700",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "Novo Nordisk hires private U.S. firm to handle some Wegovy pen assembly ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BJ4QEQBPHZJKDBODH4TQ3GKRCI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.17076,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.053201",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk shares fall after media report about quality lapses at U.S. plant",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-shares-fall-after-media-report-about-quality-lapses-us-plant-2023-09-18/",
            "time_published": "20230918T113600",
            "authors": [
                "Reuters"
            ],
            "summary": "Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/HKTER5Y4FBO3BAFYYIBBMNXRBI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.002358,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "-0.084954",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 4 Dividend ETFs Are a Retiree's Best Friend",
            "url": "https://www.fool.com/investing/2023/09/18/these-4-dividend-etfs-are-a-retirees-best-friend/",
            "time_published": "20230918T103500",
            "authors": [
                "Selena Maranjian"
            ],
            "summary": "Dividends can be powerful wealth-boosters in your portfolio, delivering regular (and often growing) income.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999346"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.21036,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.048915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMT",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLD",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TD",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.048915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.093906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EQIX",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.048915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSA",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Vanguard International Dividend Appreciation ETF  ( VIGI )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2151655/is-vanguard-international-dividend-appreciation-etf-vigi-a-strong-etf-right-now",
            "time_published": "20230918T102007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default242.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                }
            ],
            "overall_sentiment_score": 0.249128,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.263261",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.059001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.059001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Stock-Split Stocks Billionaire Investors Can't Stop Buying",
            "url": "https://www.fool.com/investing/2023/09/18/3-stock-split-stocks-billionaires-cant-stop-buying/",
            "time_published": "20230918T092100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three highfliers Wall Street's top managers are piling into.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F747886%2Fpaper-certificate-shares-invest-stock-split-market-reverse-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.17858,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.032736",
                    "ticker_sentiment_score": "0.05142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.194502",
                    "ticker_sentiment_score": "0.157816",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.257328",
                    "ticker_sentiment_score": "0.061524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.2261",
                    "ticker_sentiment_score": "0.131275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.032736",
                    "ticker_sentiment_score": "0.014335",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html",
            "time_published": "20230918T083500",
            "authors": [],
            "summary": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.157274,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic maker Novo Nordisk isn't just Europe's second-most valuable company. It is also singlehandedly boosting Denmark's economy.",
            "url": "https://www.businessinsider.com/weight-loss-ozempic-wegovy-novo-nordisk-market-cap-denmark-economy-2023-9",
            "time_published": "20230918T043000",
            "authors": [
                "Huileng Tan"
            ],
            "summary": "Ozempic maker Novo Nordisk boosting Denmark's economy - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.139895,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.086081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.119042",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Shortage Of Weight-Loss Drugs Like Wegovy And Ozempic Persist-And Could For 'Some Years'",
            "url": "https://www.forbes.com/sites/brianbushard/2023/09/16/shortage-of-weight-loss-drugs-like-wegovy-and-ozempic-persist-and-could-for-some-years/",
            "time_published": "20230916T152750",
            "authors": [
                "Brian Bushard"
            ],
            "summary": "Diabetes drugs Wegovy and Ozempic, which have gained popularity as weight-loss drugs, face major supply issues, drugmaker Novo Nordisk admitted, as the company struggles with surging demand.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6505c91cb7a38a290928ff0b/0x0.jpg?format=jpg&crop=3326,1869,x0,y169,safe&width=1200",
            "source": "Forbes",
            "category_within_source": "Business",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.007301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.002018",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Supply problems and insurance issues make popular weight-loss drugs hard to get",
            "url": "https://apnews.com/article/wegovy-ozempic-mounjaro-shortage-insurance-64014bc2887a518b33c597b2bf936e37",
            "time_published": "20230916T120100",
            "authors": [
                "TOM MURPHY"
            ],
            "summary": "When she prescribes the , Dr. Angela Fitch sends patients on a quest she likens to \"The Hunger Games.\" They will have to call drugstores over several days to find one with the properly sized first dose. Then they'll do that again for their second dose, and probably the third.",
            "banner_image": "https://dims.apnews.com/dims4/default/5d307a9/2147483647/strip/true/crop/3040x2025+280+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F93%2F27%2F86bf882da64e80df87b27e3e6459%2F56afd3f642d54664acf0262ac3eb7f12",
            "source": "Associated Press",
            "category_within_source": "Business",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.096965,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHC",
                    "relevance_score": "0.037681",
                    "ticker_sentiment_score": "0.16207",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075279",
                    "ticker_sentiment_score": "-0.136558",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Growth Stock That Could Turn $1,000 Into $2,500 by 2030",
            "url": "https://www.fool.com/investing/2023/09/16/1-growth-stock-that-could-turn-1000-into-2500-by-2/",
            "time_published": "20230916T111500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The stock has delivered market-beating returns in the past. It can do it again.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.224724,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.230381",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.068966",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Yet Again, Ozempic Could Soon Get Even Better for Novo Nordisk Stock",
            "url": "https://www.fool.com/investing/2023/09/16/yet-again-ozempic-could-soon-get-even-better-for-n/",
            "time_published": "20230916T110500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The results of a small new study could open the door to yet another market.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.207938,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.11891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.275246",
                    "ticker_sentiment_score": "0.224489",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S  ( NYSE:NVO )  Stock Rating Lowered by StockNews.com",
            "url": "https://www.defenseworld.net/2023/09/16/novo-nordisk-a-s-nysenvo-stock-rating-lowered-by-stocknews-com.html",
            "time_published": "20230916T075441",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "Novo Nordisk A/S ( NYSE:NVO ) Stock Rating Lowered by ... Defense World ...",
            "banner_image": "https://www.marketbeat.com/logos/novo-nordisk-logo.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.273661,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.226757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ENV",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.226757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.226757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.871234",
                    "ticker_sentiment_score": "0.455662",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Adobe  ( ADBE )  Q3 Earnings & Revenues Beat Estimates, Rise Y/Y",
            "url": "https://www.zacks.com/stock/news/2149711/adobe-adbe-q3-earnings-revenues-beat-estimates-rise-yy",
            "time_published": "20230915T153200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Adobe's (ADBE) fiscal third-quarter results benefit from the strong momentum across Creative Cloud, Document Cloud and Experience Cloud.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                }
            ],
            "overall_sentiment_score": 0.314733,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ASUR",
                    "relevance_score": "0.157483",
                    "ticker_sentiment_score": "0.155715",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.196132",
                    "ticker_sentiment_score": "0.176635",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DG",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.163843",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.2387",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.163843",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.573213",
                    "ticker_sentiment_score": "0.518286",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "EMR",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.2387",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.163843",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMI",
                    "relevance_score": "0.157483",
                    "ticker_sentiment_score": "0.155715",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "My Top Small-Cap Pick for a Strong Year-End Run",
            "url": "https://realmoney.thestreet.com/investing/stocks/my-top-small-cap-pick-for-a-strong-year-end-run-16133297",
            "time_published": "20230915T153000",
            "authors": [
                "James \"Rev Shark\" DePorre"
            ],
            "summary": "On Tuesday, I discussed Uber ( UBER ) , which is my top large-cap pick for a strong year-end run. Today, I want to discuss my top small-cap pick for a strong year-end run. My pick is LifeMD ( LFMD ) . LifeMD has a market cap of around $168 million with about 36 million shares outstanding.",
            "banner_image": "https://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/a49b1bcd-5333-11ee-92a9-11685bebb03f.jpg",
            "source": "The Street",
            "category_within_source": "GoogleRSS",
            "source_domain": "realmoney.thestreet.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.239314,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.163769",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.002841",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MED",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "-0.024638",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.496199",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.163769",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More",
            "url": "https://www.zacks.com/stock/news/2149445/pharma-stock-roundup-fda-nod-to-updated-pfe-mrna-covid-jabs-more",
            "time_published": "20230915T133300",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.059775,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.031869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.315493",
                    "ticker_sentiment_score": "0.13387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.031869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.265089",
                    "ticker_sentiment_score": "0.093183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.364529",
                    "ticker_sentiment_score": "0.081749",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.036452",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET - Lahontan Gold  ( OTC:LGCXF ) ",
            "url": "https://www.benzinga.com/pressreleases/23/09/g34615284/new-to-the-street-announces-episodes-510-and-511-six-corporate-interviews-airings-on-newsmax-and-f",
            "time_published": "20230915T133000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- FMW Media's New to The Street announces their corporate interviews for episodes 510 and 511 that will air on Newsmax and the FOX Business Network. 1 ) . Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s TNXP ( $TNXP ) interview with Dr. Seth ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.197045,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.022969",
                    "ticker_sentiment_score": "0.155393",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.011485",
                    "ticker_sentiment_score": "-0.012651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNXP",
                    "relevance_score": "0.125818",
                    "ticker_sentiment_score": "-0.011911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.011485",
                    "ticker_sentiment_score": "0.048976",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 No-Brainer Stocks That Could Make You Richer",
            "url": "https://www.fool.com/investing/2023/09/15/2-no-brainer-stocks-that-could-make-you-richer/",
            "time_published": "20230915T123000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Both companies have trounced the market over the past five years.",
            "banner_image": "https://media.ycharts.com/charts/765239b02c796dae65aa059ba7819a3f.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.287647,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MFCSF",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VEEV",
                    "relevance_score": "0.51278",
                    "ticker_sentiment_score": "0.207637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.148268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.148268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCA",
                    "relevance_score": "0.430251",
                    "ticker_sentiment_score": "0.440128",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3  ( Bad )  Reasons to Avoid or Sell Novo Nordisk Stock",
            "url": "https://www.fool.com/investing/2023/09/15/3-bad-reasons-to-avoid-or-sell-novo-nordisk-stock/",
            "time_published": "20230915T114500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The rhetoric surrounding popular businesses isn't always good advice.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.004915,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.241924",
                    "ticker_sentiment_score": "-0.105412",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Top Healthcare Stocks Defying the Bear Market",
            "url": "https://www.fool.com/investing/2023/09/15/3-top-healthcare-stocks-defying-the-bear-market/",
            "time_published": "20230915T094900",
            "authors": [
                "Jim Halley"
            ],
            "summary": "Revenue at all three companies improved last quarter, and their share prices have followed suit.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99994"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.179087,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.240886",
                    "ticker_sentiment_score": "0.104128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.04076",
                    "ticker_sentiment_score": "0.073671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081414",
                    "ticker_sentiment_score": "-0.179842",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ozempic-Maker Invests in Renewables",
            "url": "https://www.thedailyupside.com/industries/energy/ozempic-maker-invests-in-renewables/",
            "time_published": "20230914T225707",
            "authors": [
                "Isobel Asher Hamilton"
            ],
            "summary": "The company that makes waistline-shrinking Ozempic is taking advantage of shrinking valuations for green energy companies. Novo Holdings, a...",
            "banner_image": null,
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.thedailyupside.com",
            "topics": [
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.110672,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.380012",
                    "ticker_sentiment_score": "0.144149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "-0.133297",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Gains But Lags Market: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2149164/novo-nordisk-nvo-gains-but-lags-market-what-you-should-know",
            "time_published": "20230914T215019",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Novo Nordisk (NVO) closed at $192.87, marking a +0.12% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default76.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.193162,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.606946",
                    "ticker_sentiment_score": "0.336601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,700 Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/earnings/23/09/34592699/1000-invested-in-this-stock-10-years-ago-would-be-worth-5-700-today",
            "time_published": "20230914T193022",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.94% on an annualized basis producing an average annual return of 18.98%. Currently, Novo Nordisk has a market capitalization of $865.16 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Announces Stock Split to Enhance Liquidity",
            "url": "https://www.zacks.com/stock/news/2149069/novo-nordisk-nvo-announces-stock-split-to-enhance-liquidity",
            "time_published": "20230914T152800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.081997,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.314017",
                    "ticker_sentiment_score": "0.131476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.482304",
                    "ticker_sentiment_score": "0.063392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.314017",
                    "ticker_sentiment_score": "0.041002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Notification of managers' transactions",
            "url": "https://www.globenewswire.com/news-release/2023/09/14/2743487/0/en/Notification-of-managers-transactions.html",
            "time_published": "20230914T152000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.119699,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.282234",
                    "ticker_sentiment_score": "0.124107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.282234",
                    "ticker_sentiment_score": "0.124107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.282234",
                    "ticker_sentiment_score": "0.124107",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Stock Is Lifting an Entire Country's Economy -- Is It a Buy?",
            "url": "https://www.fool.com/investing/2023/09/14/this-stock-is-lifting-an-entire-countrys-economy/",
            "time_published": "20230914T133000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The drugmaker is clearly firing on all cylinders.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.267022,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.550532",
                    "ticker_sentiment_score": "0.342212",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Buy Ozempic Maker Novo Nordisk Before Its Stock Split?",
            "url": "https://www.fool.com/investing/2023/09/14/buy-ozempic-maker-novo-nordisk-before-stock-split/",
            "time_published": "20230914T095200",
            "authors": [
                "Keith Speights"
            ],
            "summary": "The upcoming stock split isn't the main story with this high-flying pharma stock.",
            "banner_image": "https://media.ycharts.com/charts/e8ecadc6473830b487870c09614dcc17.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.017111,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.455525",
                    "ticker_sentiment_score": "0.136503",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bernard Arnault Built a Luxury Empire on 'Desirability.' Who Will Inherit It?",
            "url": "https://www.nytimes.com/2023/09/14/business/bernard-arnault-lvmh-family-succession.html",
            "time_published": "20230914T090033",
            "authors": [
                "Vanessa Friedman",
                "Liz Alderman"
            ],
            "summary": "With brands like Tiffany, Dom Pérignon and Louis Vuitton, LVMH turned him into one of the world's richest men. But with five children, he has a hard decision to make.",
            "banner_image": "https://static01.nyt.com/images/2023/09/07/multimedia/00RICHESTMAN-kmlg/00RICHESTMAN-kmlg-articleLarge.jpg?quality=75&auto=webp&disable=upscale",
            "source": "New York Times",
            "category_within_source": "Business",
            "source_domain": "www.nytimes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.113947,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.012882",
                    "ticker_sentiment_score": "-0.055506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.012882",
                    "ticker_sentiment_score": "0.055237",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHDRF",
                    "relevance_score": "0.038634",
                    "ticker_sentiment_score": "0.06219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.012882",
                    "ticker_sentiment_score": "0.089804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:CHF",
                    "relevance_score": "0.012882",
                    "ticker_sentiment_score": "-0.105921",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie",
            "url": "https://www.zacks.com/stock/news/2148692/zacks-investment-ideas-feature-highlights-novo-nordisk-eli-lilly-and-abbvie",
            "time_published": "20230914T090000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.14237,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337427",
                    "ticker_sentiment_score": "0.312738",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.337427",
                    "ticker_sentiment_score": "0.312738",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.393752",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic maker Novo drops After first stock split in a decade",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-maker-novo-drops-after-first-stock-split-in-a-decade/3242668/",
            "time_published": "20230914T033000",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Novo Nordisk A/S shares fell on Wednesday in the first trading session following a split aimed at increasing the liquidity of the Danish drugmaker's soaring stock.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/painkillers-g0651a5da2_1920-2.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.190964,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "-0.005294",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "0.099239",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.137609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBS",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "-0.004301",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742833/0/en/Annual-Report-2022-23-Continued-solid-earnings-but-weaker-growth-amid-challenging-market-conditions.html",
            "time_published": "20230913T175000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.233703,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.065685",
                    "ticker_sentiment_score": "0.061067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.065685",
                    "ticker_sentiment_score": "0.061067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.065685",
                    "ticker_sentiment_score": "0.061067",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Is What Whales Are Betting On Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/09/34546143/this-is-what-whales-are-betting-on-novo-nordisk",
            "time_published": "20230913T174633",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bearish stance on Novo Nordisk NVO. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.106229,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.795859",
                    "ticker_sentiment_score": "0.290221",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Guidance for the 2023/24 financial year",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742832/0/en/Guidance-for-the-2023-24-financial-year.html",
            "time_published": "20230913T174500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.140299,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.130157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.130157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.130157",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-weighs-in-on-inflation-vaccine-maker-leads-sp-500/",
            "time_published": "20230913T163000",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Stock Market Weighs In On Inflation Data. Vaccine Maker Leads ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-JB-Hunt-02-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.159269,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "UAL",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "-0.037062",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRS",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "0.092326",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.081006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "0.112985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SAVE",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "-0.014957",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAL",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "0.013274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LUV",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "-0.037062",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "-0.082331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCKT",
                    "relevance_score": "0.095327",
                    "ticker_sentiment_score": "0.138345",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "0.145552",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Stock Once Jumped 268% On FDA Action; Can It Do That Again?",
            "url": "https://www.investors.com/news/technology/mdgl-stock-jumps-as-its-nash-treatment-toes-the-long-awaited-finish-line/",
            "time_published": "20230913T160900",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "MDGL Stock Jumps As Its NASH Treatment Toes The Long-Awaiting ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-biotech-05-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.262821,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SLRN",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.11589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.136499",
                    "ticker_sentiment_score": "0.231953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.136499",
                    "ticker_sentiment_score": "0.159342",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.136499",
                    "ticker_sentiment_score": "0.159342",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.393977",
                    "ticker_sentiment_score": "0.491279",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "-0.191908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "-0.191908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742717/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20230913T153300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 13 September 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": 0.105523,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.039972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.039972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.719473",
                    "ticker_sentiment_score": "0.13959",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "NVO: 3 A-Rated Pharma Stocks to Buy Today",
            "url": "https://stocknews.com/news/nvo-abbv-nbix-3-a-rated-pharma-stocks-to-buy-today/",
            "time_published": "20230913T133222",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "The pharmaceutical industry is poised for robust growth, fueled by a rapidly expanding medicinal drug and vaccine market. Due to the persistent necessity of its products, the industry retains stability, which makes it less vulnerable to economic fluctuations.",
            "banner_image": "https://stocknews.com/wp-content/uploads/2021/07/shutterstock_757996678-1-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                }
            ],
            "overall_sentiment_score": 0.284404,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.261372",
                    "ticker_sentiment_score": "0.144445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.238367",
                    "ticker_sentiment_score": "0.177456",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NBIX",
                    "relevance_score": "0.120551",
                    "ticker_sentiment_score": "0.106094",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "TIME Reveals the 2023 TIME100 Next List of the World's Rising Stars - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/time-reveals-the-2023-time100-next-list-of-the-worlds-rising-stars-301925732.html",
            "time_published": "20230913T120100",
            "authors": [],
            "summary": "TIME Reveals the 2023 TIME100 Next List of the World's Rising Stars PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.241825,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VZ",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "0.143517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "-0.038914",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "0.143517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:UYU",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "0.13853",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Altimmune  ( ALT )  Rises 7% on Completing Dosing in Obesity Study",
            "url": "https://www.zacks.com/stock/news/2148179/altimmune-alt-rises-7-on-completing-dosing-in-obesity-study",
            "time_published": "20230913T113000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.155306,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.180637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.239752",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.088988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.234006",
                    "ticker_sentiment_score": "0.129318",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk conducts a two-for-one stock split",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742171/0/en/Novo-Nordisk-conducts-a-two-for-one-stock-split.html",
            "time_published": "20230913T053000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 13 September 2023 - As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, Novo Nordisk's Board of Directors has approved a split of the trading units of the Novo Nordisk B shares listed on Nasdaq ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                }
            ],
            "overall_sentiment_score": 0.016821,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.080389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.080389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.618922",
                    "ticker_sentiment_score": "0.043415",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wall Street Has Found Its Next High-Flying Stock-Split Stock. Here's Why I'm Not Buying the Hype.",
            "url": "https://www.fool.com/investing/2023/09/12/wall-street-has-next-high-flying-stock-split-stock/",
            "time_published": "20230912T090600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, and Monster Beverage have all split their shares since July 2021. Next week, another industry leader will join this exclusive club.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F747197%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.147951,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.147186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.147186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.147186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.270996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.399856",
                    "ticker_sentiment_score": "0.150249",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.142446",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.147186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.142446",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, Booking Holdings, Sony and EOG",
            "url": "https://www.zacks.com/stock/news/2147534/the-zacks-analyst-blog-highlights-microsoft-novo-nordisk-booking-holdings-sony-and-eog",
            "time_published": "20230912T090500",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Microsoft, Novo Nordisk, Booking Holdings, Sony and EOG are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/86.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.324237,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.256989",
                    "ticker_sentiment_score": "0.136233",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNEJF",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.037423",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EOG",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.037423",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.318074",
                    "ticker_sentiment_score": "0.332834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.318074",
                    "ticker_sentiment_score": "0.250563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.065327",
                    "ticker_sentiment_score": "-0.017232",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European shares muted, SAP drags Germany's DAX down",
            "url": "https://www.reuters.com/markets/europe/european-shares-edge-higher-softer-pound-lifts-uks-ftse-100-2023-09-12/",
            "time_published": "20230912T084200",
            "authors": [
                "Bansari Kamdar"
            ],
            "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, August 23, 2023. REUTERS/Staff/File Photo Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/BRITAIN-ECONOMY/UNEMPLOYMENT/gdvzwmezapw/chart.png",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.116199,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EADSF",
                    "relevance_score": "0.165598",
                    "ticker_sentiment_score": "-0.106664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WRK",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.208321",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ASBFF",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.231061",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MNXBF",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.212897",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SMFTF",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.208321",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.144386",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stock Reports for Microsoft, Novo Nordisk & Booking Holdings",
            "url": "https://www.zacks.com/research-daily/2147209/top-stock-reports-for-microsoft-novo-nordisk-booking-holdings",
            "time_published": "20230911T163200",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and Booking Holdings Inc. (BKNG).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.391015,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.171919",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.175221",
                    "ticker_sentiment_score": "0.38592",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.175221",
                    "ticker_sentiment_score": "0.30212",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "-0.01815",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": " ( NVO )  - Analyzing Novo Nordisk's Short Interest - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/short-sellers/23/09/34449118/nvo-analyzing-novo-nordisks-short-interest",
            "time_published": "20230911T163022",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has risen 100.0% since its last report. The company recently reported that it has 2.05 million shares sold short, which is 0.12% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.267332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.155473",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus",
            "url": "https://www.zacks.com/stock/news/2147094/take-the-zacks-approach-to-beat-the-market-shopify-novo-nordisk-amgen-in-focus",
            "time_published": "20230911T120100",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/1179.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.170879,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.132382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BZH",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.260272",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HQY",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.279454",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OFG",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.279454",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRS",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.142432",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PAYX",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.060269",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.06212",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.06212",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.060269",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.106267",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.10087",
                    "ticker_sentiment_score": "0.112974",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - BlackRock, Inc.",
            "url": "https://www.globenewswire.com/news-release/2023/09/11/2740670/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
            "time_published": "20230911T111500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.142316,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.666827",
                    "ticker_sentiment_score": "0.299741",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.076328",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.076328",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.076328",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Hartford Multifactor Developed Markets  ( ex-US )  ETF  ( RODM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2147013/is-hartford-multifactor-developed-markets-ex-us-etf-rodm-a-strong-etf-right-now",
            "time_published": "20230911T102007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default98.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.138323,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "-0.016011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "-0.016011",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Did Ozempic Play A Role In A Man's Suicide? Family Seeks Warning Label - Novo Nordisk  ( OTC:NONOF ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34428787/did-ozempic-play-a-role-in-a-mans-suicide-family-seeks-warning-label",
            "time_published": "20230911T084052",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "The family of a man who died by suicide is seeking a warning label on the 'miracle' weight loss drug Ozempic, claiming it contributed to his death, NBC News reported. The family believes the man's mood changes were linked to his use of Type 2 diabetes medicine.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/OZempic_Insulin_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.227083,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "-0.026601",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Female Sexual Dysfunction Treatment Market to grow by USD 7.76 billion from 2022-2027; North America to account ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/female-sexual-dysfunction-treatment-market-to-grow-by-usd-7-76-billion-from-2022-2027-north-america-to-account-for-61-of-market-growth---technavio-301922154.html",
            "time_published": "20230911T073500",
            "authors": [],
            "summary": "Female Sexual Dysfunction Treatment Market to grow by USD 7.76 billion from 2022-2027. North America to account ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.256383,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MITPF",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENDPQ",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "0.023502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DARE",
                    "relevance_score": "0.049019",
                    "ticker_sentiment_score": "0.043476",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors - here's what we know",
            "url": "https://www.cnbc.com/2023/09/10/ozempic-wegovy-drinking-smoking-what-we-know.html",
            "time_published": "20230910T130001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Scientists hope that a new class of treatments for alcohol use disorder, smoking and other addictive behaviors is on the horizon.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107297619-1694173880625-gettyimages-1644962392-arriens-ozempicm230903_nppEk.jpeg?v=1694350801&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.097858,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057284",
                    "ticker_sentiment_score": "-0.101954",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double",
            "url": "https://www.fool.com/investing/2023/09/10/cathie-wood-is-buying-these-2-biotech-stocks-hand/",
            "time_published": "20230910T121500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "These businesses could be on the verge of takeoff.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.238473,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DNA",
                    "relevance_score": "0.151222",
                    "ticker_sentiment_score": "0.185105",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.191367",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NTLA",
                    "relevance_score": "0.151222",
                    "ticker_sentiment_score": "0.19266",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.",
            "url": "https://www.fool.com/investing/2023/09/10/investors-may-not-have-seen-the-best-from-eli-lill/",
            "time_published": "20230910T101200",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Mounjaro has been on the market for roughly one year and is already generating billions in sales for Eli Lilly. But with that said, its best days could be ahead.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745741%2Fgettyimages-1315185865.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.15603,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.609866",
                    "ticker_sentiment_score": "0.228644",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303926",
                    "ticker_sentiment_score": "0.023955",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion",
            "url": "https://www.cnbc.com/2023/09/09/big-pharma-blockbuster-obesity-drug-battle-is-headed-for-100-billion.html",
            "time_published": "20230909T131942",
            "authors": [
                "Bob Woods"
            ],
            "summary": "As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107283911-16915918071691591804-30690758274-1080pnbcnews.jpg?v=1691593646&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.122593,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04028",
                    "ticker_sentiment_score": "0.167372",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "-0.023001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.020146",
                    "ticker_sentiment_score": "0.030343",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Top Healthcare Stocks to Buy for September",
            "url": "https://www.fool.com/investing/2023/09/09/3-top-healthcare-stocks-to-buy-for-september/",
            "time_published": "20230909T131500",
            "authors": [
                "Justin Pope"
            ],
            "summary": "These blue-chip healthcare stocks are trading at attractive valuations today.",
            "banner_image": "https://media.ycharts.com/charts/e436a8f10d6d7189188f44e1420a3de2.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.322143,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.012445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.147592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.288213",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.056984",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Gains But Lags Market: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2146845/novo-nordisk-nvo-gains-but-lags-market-what-you-should-know",
            "time_published": "20230908T215017",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Novo Nordisk (NVO) closed at $195.40, marking a +0.01% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default179.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.200065,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.330262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Fed could lose $100B - Does this spell catastrophe for Bitcoin?",
            "url": "https://cointelegraph.com/news/fed-could-lose-100-billion-does-this-spell-catastrophe-bitcoin",
            "time_published": "20230908T183000",
            "authors": [
                "Marcel Pechman"
            ],
            "summary": "On the latest episode of \"Macro Markets,\" Marcel Pechman explains the potential implications for crypto of the Federal Reserve losing $100 billion.",
            "banner_image": "https://images.cointelegraph.com/images/1200_aHR0cHM6Ly9zMy5jb2ludGVsZWdyYXBoLmNvbS91cGxvYWRzLzIwMjMtMDkvN2E1ZDA2NWQtOGY4ZC00YmEyLThkYTktMmE1N2E1Yzk1YWY1LmpwZw==.jpg",
            "source": "Cointelegraph",
            "category_within_source": "n/a",
            "source_domain": "cointelegraph.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.149763,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "0.328487",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.",
            "url": "https://www.businessinsider.com/obesity-economic-cost-4-trillion-wegovy-ozempic-weight-loss-drugs-2023-9",
            "time_published": "20230908T174400",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Obesity's economic cost is expected to soar to $4 trillion by 2035 - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.13661,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.33514",
                    "ticker_sentiment_score": "-0.01197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.33514",
                    "ticker_sentiment_score": "0.343543",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Drug in Ozempic may enable patients with newly diagnosed type 1 diabetes to stave off insulin use, small study suggests",
            "url": "https://www.cnn.com/2023/09/08/health/ozempic-diabetes-semaglutide-study/index.html",
            "time_published": "20230908T155400",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "A weekly dose of semaglutide, the key ingredient in blockbuster medications Ozempic and Wegovy, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months in a small study.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230504164653-wegovy-limits-052023.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.100833,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.292922",
                    "ticker_sentiment_score": "0.160681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "-0.034627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNDM",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "-0.034627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.149038",
                    "ticker_sentiment_score": "0.04939",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CPRX: September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals  ( CPRX ) ",
            "url": "https://stocknews.com/news/cprx-nvs-nvo-snphy-september-buy-sell-or-hold-for-this-pharma-sock-catalyst/",
            "time_published": "20230908T144312",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "CPRX: September Buy, Sell or Hold for This Pharma Sock: Catalyst ... ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2021/01/cvs-rad-wba-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.131144,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.060617",
                    "ticker_sentiment_score": "0.151025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CPRX",
                    "relevance_score": "0.597127",
                    "ticker_sentiment_score": "0.098862",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPHF",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "0.142381",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060617",
                    "ticker_sentiment_score": "0.151025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "1 Stock Split Stock to Buy Hand Over Fist Right Now",
            "url": "https://www.fool.com/investing/2023/09/08/1-stock-split-stock-to-buy-hand-over-fist-now/",
            "time_published": "20230908T134500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk stock is up nearly 40% so far in 2023. But it could be headed even higher in short order.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745914%2Fgettyimages-1471076000.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.779048"
                }
            ],
            "overall_sentiment_score": 0.260321,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.582526",
                    "ticker_sentiment_score": "0.407253",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "UK Authority Recommends Eli Lilly's Famed Diabetes Drug Mounjaro As New Treatment Option For Type 2 Diabetes - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34358238/uk-authority-recommends-eli-lillys-famed-diabetes-drug-mounjaro-as-new-treatment-option-for-type-",
            "time_published": "20230908T133815",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "UK's National Institute for Health and Care Excellence ( NICE ) has endorsed Eli Lilly And Co's LLY diabetes medication, Mounjaro ( tirzepatide ) , indicating it as a viable option for patients grappling with poorly controlled type 2 diabetes.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/lly.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.402868,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.470894",
                    "ticker_sentiment_score": "0.513297",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.325208",
                    "ticker_sentiment_score": "0.079727",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Topped the Market on Thursday",
            "url": "https://www.fool.com/investing/2023/09/07/why-novo-nordisk-stock-topped-the-market-on-thursd/",
            "time_published": "20230907T220347",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The company behind Wegovy got a bullish boost from a top group of prognosticators.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.303982,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.423096",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.760593",
                    "ticker_sentiment_score": "0.477827",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Futures: Nasdaq Breaks 50-Day, Holds This; 4 Stocks Near Buy Points",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-breaks-support-holds-this-key-level-meta-3-stocks-near-buy-points/",
            "time_published": "20230907T205500",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Futures: Nasdaq Breaks 50-Day, Holds This. 4 Stocks Near Buy Points Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/stock-bear-bull-reflect-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": -0.036426,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "0.161688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.07793",
                    "ticker_sentiment_score": "-0.044525",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "-0.203123",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.230843",
                    "ticker_sentiment_score": "-0.30945",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "-0.006449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.07793",
                    "ticker_sentiment_score": "0.124764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "-0.088491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMAR",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.173554",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.180557",
                    "ticker_sentiment_score": "0.153336",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "-0.032036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RH",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.009166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "0.161688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HUBS",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.173554",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QRVO",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "-0.032036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.042871",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.02435",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Factal Debuts Incident Chat to Connect Companies in Proximity to the Same Crisis",
            "url": "https://www.prnewswire.com/news-releases/factal-debuts-incident-chat-to-connect-companies-in-proximity-to-the-same-crisis-301921046.html",
            "time_published": "20230907T162100",
            "authors": [
                "Factal"
            ],
            "summary": "SEATTLE, Sept. 7, 2023 /PRNewswire/ -- is announcing the launch of , a groundbreaking new feature that enables organizations to share emergency information in a secure chat when they're faced with the same critical incident.",
            "banner_image": "https://mma.prnewswire.com/media/2204124/factal_logo_horizontal_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.219812,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.109956",
                    "ticker_sentiment_score": "0.19609",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Factal Debuts Incident Chat to Connect Companies in Proximity to the Same Crisis",
            "url": "https://www.benzinga.com/pressreleases/23/09/n34326625/factal-debuts-incident-chat-to-connect-companies-in-proximity-to-the-same-crisis",
            "time_published": "20230907T162100",
            "authors": [
                "PRNewswire"
            ],
            "summary": "SEATTLE, Sept. 7, 2023 /PRNewswire/ -- Factal is announcing the launch of Incident Chat, a groundbreaking new feature that enables organizations to share emergency information in a secure chat when they're faced with the same critical incident.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.21008,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.186244",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Business | Sep 9th 2023 Edition",
            "url": "https://www.economist.com/the-world-this-week/2023/09/07/business",
            "time_published": "20230907T142020",
            "authors": [
                "The Economist"
            ],
            "summary": "Country Garden, a big Chinese property developer, managed to make two interest payments to bondholders just before the end of a 30-day grace period, thus avoiding a technical default. The company had only recently warned that it might default on its debt after reporting a huge quarterly loss.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230909_WWC490.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": -0.007303,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TEF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.137177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.082019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.062884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFTBF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.107679",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRYF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.116044",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "-0.073641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QUBSF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.225887",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AZUL",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.160174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Britain's Superdrug says Wegovy received is \"very small fraction\" of waiting list",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/britains-superdrug-says-wegovy-received-is-very-small-fraction-waiting-list-2023-09-07/",
            "time_published": "20230907T141500",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "A Simple Online Pharmacy weight care provider unpacks Wegovy stock, at the Simple Online Pharmacy Headquarters, in Glasgow, Britain, September 5, 2023. Simple Online Pharmacy/Handout via REUTERS Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GTOUGHRXORIXZMOSDY6WTIAC2M.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.080492,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.226248",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2023/09/07/is-novo-nordisk-stock-a-buy-now/",
            "time_published": "20230907T140700",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Novo Nordisk recently launched Wegovy in the United Kingdom.",
            "banner_image": "https://media.ycharts.com/charts/6192a2f00bf76310dfc3425bed535dd8.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.150566,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.02213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.604961",
                    "ticker_sentiment_score": "0.232792",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.02213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.008041",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.008041",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year",
            "url": "https://www.fool.com/investing/2023/09/07/1-weight-loss-stock-thats-been-a-hotter-buy-than/",
            "time_published": "20230907T140000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Is WW International a good way to benefit from the latest healthcare trends, or has it become a risky meme stock?",
            "banner_image": "https://media.ycharts.com/charts/39bb869a9ad8128dffc123178f9e1355.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.093431,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WW",
                    "relevance_score": "0.730954",
                    "ticker_sentiment_score": "0.155136",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.127941",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Is Already Working on Ozempic 2.0. Here's How to Profit",
            "url": "https://www.fool.com/investing/2023/09/07/novo-nordisk-working-on-ozempic-how-profit/",
            "time_published": "20230907T132907",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The next version of this blockbuster drug won't be ready for a while, but it'll likely be a big earner.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.308133,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.273399",
                    "ticker_sentiment_score": "0.307961",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Popular Obesity Drugs For Dementia, Addiction Treatment? Researchers Explore Potential - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34306804/popular-obesity-drugs-for-dementia-addiction-treatment-researchers-explore-potential",
            "time_published": "20230907T112742",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Scientists are now exploring the potential of popular obesity drugs to address conditions like dementia and alcohol addiction, following recent trials that demonstrated the drugs' effectiveness in treating severe health issues.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/07/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.002406,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.391923",
                    "ticker_sentiment_score": "0.125078",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Blockbuster weight loss drugs Wegovy and Ozempic are being tested to treat addiction and dementia",
            "url": "https://www.cnbc.com/2023/09/07/weight-loss-drugs-wegovy-ozempic-tested-to-treat-addiction-dementia.html",
            "time_published": "20230907T052909",
            "authors": [
                "Karen Gilchrist"
            ],
            "summary": "Scientists have begun investigating whether so-called miracle obesity drugs can be used to help treat conditions such as dementia and alcohol addiction.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107215515-Clean_Thumb.png?v=1680500866&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072489,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.119631",
                    "ticker_sentiment_score": "-0.016383",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss 'wonder drug' Ozempic under scrutiny amid suicide risk claims",
            "url": "https://www.aljazeera.com/economy/2023/9/7/weight-loss-wonder-drug-ozempic-under-scrutiny-amid-suicide-risk-claims",
            "time_published": "20230907T024634",
            "authors": [
                "Andy Hirschfeld"
            ],
            "summary": "Ozempic has not shown increased risk of suicidal ideation in trials, but some users say it harmed their mental health. New York City, the United States - Ray Niscior of Toledo, Ohio, has struggled with his weight since he was a child.",
            "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/09/2023-09-04T101757Z_771549766_RC2JZ2AIJUV6_RTRMADP_3_HEALTH-OBESITY-NOVO-NORDISK-PHARMACY-1694047215.jpg?w=770&resize=770%2C578",
            "source": "Al Jareeza",
            "category_within_source": "n/a",
            "source_domain": "www.aljazeera.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.120615,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029292",
                    "ticker_sentiment_score": "-0.120556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.202851",
                    "ticker_sentiment_score": "0.06112",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "US stocks fall as Fed comments and new data raise fear of more rate hikes",
            "url": "https://markets.businessinsider.com/news/stocks/stock-market-news-dow-fed-rate-hikes-traders-investors-policy-2023-9",
            "time_published": "20230906T200200",
            "authors": [
                "Phil Rosen"
            ],
            "summary": "Stock Market News: Dow Tumbles As Possible Rate Hikes Spooks Investors - Markets Insider ...",
            "banner_image": "https://i.insider.com/64f8c50b8a78400019617d34?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.048402,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "-0.326883",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "LPLA",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "-0.089555",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "-0.025363",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WE",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "-0.025363",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Unusual Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/09/34292172/novo-nordisk-unusual-options-activity",
            "time_published": "20230906T194658",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bearish stance on Novo Nordisk NVO. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.164855,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.701476",
                    "ticker_sentiment_score": "0.164621",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "CGC: What Should Pharma Investors Plan to Do With Canopy Growth  ( CGC )  this Month?",
            "url": "https://stocknews.com/news/cgc-nvs-nvo-rdy-what-should-pharma-investors-plan-to-do-with-canopy-growth/",
            "time_published": "20230906T162734",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "CGC: What Should Pharma Investors Plan to Do With Canopy ... ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2021/06/shutterstock_354999077-1-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.094516,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CGC",
                    "relevance_score": "0.512322",
                    "ticker_sentiment_score": "0.094936",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050306",
                    "ticker_sentiment_score": "0.145259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.050306",
                    "ticker_sentiment_score": "0.145259",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CHART OF THE DAY: Ozempic maker Novo Nordisk overtakes LVMH to become the biggest company in Europe",
            "url": "https://markets.businessinsider.com/news/stocks/chart-of-the-day-ozempic-novo-nordisk-biggest-company-europe-2023-9",
            "time_published": "20230906T154400",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "• Novo Nordisk is now the biggest company in Europe with a valuation of more than $425 billion. • The biotech company has taken over luxury goods maker LVMH in market cap size. • Novo Nordisk has seen soaring demand for its weight-loss drugs Ozempic and Wegovy.",
            "banner_image": "https://i.insider.com/64f89adba35dd100195f32a6?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.160812,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.769861",
                    "ticker_sentiment_score": "0.352787",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Professional cycling team competing at the Grand Prix Cycliste de Montréal shows that athletic excellence is possible ... - Canada NewsWire",
            "url": "https://www.newswire.ca/news-releases/professional-cycling-team-competing-at-the-grand-prix-cycliste-de-montreal-shows-that-athletic-excellence-is-possible-when-living-with-type-1-diabetes-805615460.html",
            "time_published": "20230906T142700",
            "authors": [],
            "summary": "Professional cycling team competing at the Grand Prix Cycliste de Montréal shows that athletic excellence is possible ... Canada ...",
            "banner_image": null,
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.291761,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.691369",
                    "ticker_sentiment_score": "0.46786",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Obesity Drugs Give Danish Economy A Major Boost",
            "url": "https://www.barrons.com/news/obesity-drugs-give-danish-economy-a-major-boost-f94afd4b",
            "time_published": "20230906T122700",
            "authors": [
                "Camille BAS-WOHLERT"
            ],
            "summary": "Massive demand for diabetes and weight loss drugs made by Danish pharmaceutical group Novo Nordisk have turned it into Europe's most valuable company, giving Denmark's economy a major makeover.",
            "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.113438,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.093759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.316168",
                    "ticker_sentiment_score": "0.079647",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drugs Give Danish Economy A Major Boost",
            "url": "https://www.barrons.com/news/obesity-drugs-give-danish-economy-a-major-boost-ee9a1d9",
            "time_published": "20230906T122700",
            "authors": [
                "Camille BAS-WOHLERT"
            ],
            "summary": "Massive demand for diabetes and weight loss drugs made by Danish pharmaceutical group Novo Nordisk have turned it into Europe's most valuable company, giving Denmark's economy a major makeover.",
            "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP1023587287822169667326534516794407323186---1.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.113438,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.093759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.316168",
                    "ticker_sentiment_score": "0.079647",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.110757",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks making the biggest moves premarket: Enbridge, Roku, Gitlab and more",
            "url": "https://www.cnbc.com/2023/09/06/stocks-making-the-biggest-moves-premarket-enb-roku-gtlb.html",
            "time_published": "20230906T122154",
            "authors": [
                "Pia Singh"
            ],
            "summary": "These are the companies making headlines in premarket trading on Wednesday.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/102926456-pipeline.jpg?v=1694002914&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.143164,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ASAN",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "-0.05751",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTLB",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.137987",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "D",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.068362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.10963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENB",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.081418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMD",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.04191",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.047449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LUV",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "-0.017108",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is SPDR MSCI EAFE StrategicFactors ETF  ( QEFA )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2145175/is-spdr-msci-eafe-strategicfactors-etf-qefa-a-strong-etf-right-now",
            "time_published": "20230906T102006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999986"
                }
            ],
            "overall_sentiment_score": 0.195822,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "-0.01902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "-0.01902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Launches Wegovy in UK Amid Supply Issues",
            "url": "https://www.zacks.com/stock/news/2145039/novo-nordisk-nvo-launches-wegovy-in-uk-amid-supply-issues",
            "time_published": "20230905T175200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.203008,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.075687",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.089965",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.465709",
                    "ticker_sentiment_score": "0.358427",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.17879",
                    "ticker_sentiment_score": "0.076714",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stories Tuesday, Sep 5: Facebook News To Shut Down in Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale - Air France  ( OTC:AFLYY ) , AstraZeneca  ( NASDAQ:AZN ) ",
            "url": "https://www.benzinga.com/news/23/09/34237785/facebook-news-to-shut-down-in-europe-warner-bros-discovery-revises-outlook-as-strike-bites-mancheste",
            "time_published": "20230905T141930",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Meta Platforms Inc META announced a significant development regarding Facebook News in the U.K., France, and Germany. The dedicated news tab on Facebook, known as Facebook News, will cease to exist in early December.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/05/facevook_-tlzhfrlj6ny-unsplash_0.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.154688,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.01556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.316337",
                    "ticker_sentiment_score": "0.238782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.036101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.125995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRAF",
                    "relevance_score": "0.040622",
                    "ticker_sentiment_score": "0.044418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.16144",
                    "ticker_sentiment_score": "0.079532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MBGAF",
                    "relevance_score": "0.040622",
                    "ticker_sentiment_score": "0.178293",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "0.248203",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EADSF",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "0.065832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNSDF",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.046773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.092675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.16144",
                    "ticker_sentiment_score": "0.226054",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "0.104666",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.185919",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.153068",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MANU",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "-0.02249",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Neurophet, the first company in Korea, selected by Roche Diagnostics for Startup Creasphere's APAC innovation program",
            "url": "https://www.prnewswire.com/news-releases/neurophet-the-first-company-in-korea-selected-by-roche-diagnostics-for-startup-creaspheres-apac-innovation-program-301917230.html",
            "time_published": "20230905T130000",
            "authors": [
                "Neurophet"
            ],
            "summary": "Neurophet, the first company in Korea, selected by Roche Diagnostics for Startup Creasphere's APAC innovation ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1954882/Neurophet_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.255118,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.030892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.030892",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Weight Loss Drug Wegovy In Short Supply, Yet Goes Ahead With UK Launch - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34226494/novo-nordisks-weight-loss-drug-wegovy-in-short-supply-yet-goes-ahead-with-uk-launch",
            "time_published": "20230905T123618",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "On Monday, Novo Nordisk A/S NVO introduced its popular weight loss drug Wegovy ( semaglutide injection ) in the U.K., making it accessible through the National Health Service ( NHS ) weight management scheme for free prescriptions and in the private market.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/05/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.176651,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "0.428425",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "SomaLogic expands agreement with Novo Nordisk to 2025",
            "url": "https://www.globenewswire.com/news-release/2023/09/05/2737350/0/en/SomaLogic-expands-agreement-with-Novo-Nordisk-to-2025.html",
            "time_published": "20230905T123000",
            "authors": [
                "Inc.",
                "SomaLogic Operating Company"
            ],
            "summary": "Novo Nordisk will extend its use of SomaLogic's innovative proteomics technologies for research in cardiometabolic and other diseases Novo Nordisk will extend its use of SomaLogic's innovative proteomics technologies for research in cardiometabolic and other diseases ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/3b2153a4-4648-4359-99d9-adae0db34ad4",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.069017,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.197022",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SLGC",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.084526",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks and bonds are out of balance. Here's what could come next.",
            "url": "https://www.marketwatch.com/story/stocks-and-bonds-are-out-of-balance-heres-what-could-come-next-7ce32b58",
            "time_published": "20230905T122700",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "The earnings-to-price ratio on the S&P 500 is on the verge of being overtaken by the 10-year Treasury. How it may get resolved.",
            "banner_image": "https://images.mktw.net/im-846726?width=700&height=412",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999956"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                }
            ],
            "overall_sentiment_score": 0.024227,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LNC",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.10746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NWL",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.10746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.10746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.312142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRYF",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "-0.127001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.10746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "-0.02176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GME",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus",
            "url": "https://www.zacks.com/stock/news/2144752/beat-the-market-the-zacks-way-nvidia-novo-nordisk-matson-in-focus",
            "time_published": "20230905T120600",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/98.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                }
            ],
            "overall_sentiment_score": 0.226287,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BR",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.063116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.212844",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.063116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCC",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.279407",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.100588",
                    "ticker_sentiment_score": "0.107531",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.101236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CME",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.135379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MATX",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.260229",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.061268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.061268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVT",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.279407",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Markets Remain Anxious, Despite Falling Odds of a Recession",
            "url": "https://www.nytimes.com/2023/09/05/business/dealbook/markets-falling-recession-odds.html",
            "time_published": "20230905T115144",
            "authors": [
                "Sarah Kessler",
                "Andrew Ross Sorkin",
                "Lauren Hirsch",
                "Ephrat Livni",
                "Michael J. de la Merced",
                "Ravi Mattu",
                "Bernhard Warner"
            ],
            "summary": "Some economists are playing down the chances of an economic downturn. But investors and voters aren't feeling nearly as optimistic.",
            "banner_image": "https://static01.nyt.com/images/2023/09/05/multimedia/05db-markets-tchv/05db-markets-tchv-articleLarge.jpg?quality=75&auto=webp&disable=upscale",
            "source": "New York Times",
            "category_within_source": "Dealbook",
            "source_domain": "www.nytimes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": -0.093445,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "-0.121789",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "-0.010442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.009256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXGN",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.076721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.124588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRYF",
                    "relevance_score": "0.041791",
                    "ticker_sentiment_score": "-0.13078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCZ",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.092308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "-0.185064",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GME",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.059588",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The maker of Wegovy and Ozempic is now Europe's most valuable company | Business",
            "url": "https://www.cnn.com/2023/09/05/investing/novo-nordisk-wegovy-europe-stock/index.html",
            "time_published": "20230905T111200",
            "authors": [
                "Hanna Ziady"
            ],
            "summary": "The maker of Wegovy and Ozempic is now Europe's most valuable company ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230905091018-novo-nordisk-hq.jpg?c=16x9&q=h_720,w_1280,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.087701,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.38716",
                    "ticker_sentiment_score": "-0.016568",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.171688",
                    "ticker_sentiment_score": "0.099678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.227538",
                    "ticker_sentiment_score": "0.123183",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The maker of Wegovy and Ozempic is now Europe's most valuable company | Business",
            "url": "https://edition.cnn.com/2023/09/05/investing/novo-nordisk-wegovy-europe-stock/index.html",
            "time_published": "20230905T111200",
            "authors": [
                "Hanna Ziady"
            ],
            "summary": "The maker of Wegovy and Ozempic is now Europe's most valuable company CNN International ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230905091018-novo-nordisk-hq.jpg?c=16x9&q=h_720,w_1280,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "edition.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.087701,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.38716",
                    "ticker_sentiment_score": "-0.016568",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.171688",
                    "ticker_sentiment_score": "0.099678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.227538",
                    "ticker_sentiment_score": "0.123183",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic and Wegovy maker 'just scratching the surface' in meeting demand for weight loss drugs, CEO says",
            "url": "https://www.cnn.com/2023/09/05/health/novo-nordisk-jorgensen-wegovy-ozempic/index.html",
            "time_published": "20230905T104400",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "It could take years before Novo Nordisk has fulfilled demand for its highly popular weight loss drug, the company's chief executive told CNN, noting that there are more than 100 million Americans with obesity and that \"many of those would like to be on treatment.\"",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230821080822-wegovy-drug-restricted.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.00243,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.234458",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142005",
                    "ticker_sentiment_score": "0.096794",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Business is booming for the maker of weight-loss drugs Wegovy and Ozempic - so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firm",
            "url": "https://www.businessinsider.com/novo-nordisk-lvmh-europes-most-valuable-firm-wegovy-ozempic-drugs-2023-9",
            "time_published": "20230905T103200",
            "authors": [
                "Grace Dean"
            ],
            "summary": "Novo Nordisk competes with LVMH to be Europe's most valuable firm - Business Insider ...",
            "banner_image": "https://i.insider.com/64f6fddc1b7ced0019c807f6?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.106582,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362065",
                    "ticker_sentiment_score": "0.117609",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Morning Bid: China optimism dissipates after weak data",
            "url": "https://www.reuters.com/markets/global-markets-view-europe-2023-09-05/",
            "time_published": "20230905T040743",
            "authors": [
                "Reuters"
            ],
            "summary": "A look at the day ahead in European and global markets from Ankur Banerjee Investor sentiment on China remains fragile, with Monday's wave of optimism giving way on Tuesday to rekindled worries about the world's second-biggest economy, after the release of a new set of weak data.",
            "banner_image": "https://graphics.reuters.com/CHINA-PROPERTY/COUNTRYGARDEN/gdpzwmrkbvw/chart.png",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.125901,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTRYF",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.336504",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09402",
                    "ticker_sentiment_score": "0.291214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.054516",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "NVO: Top 3 Pharma Stocks to Boost Your Portfolio",
            "url": "https://stocknews.com/news/nvo-abbv-nvs-top-3-pharma-stocks-to-boost-your-portfolio/",
            "time_published": "20230904T175230",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "The pharmaceutical industry is expected to continue to grow in the coming years, driven by factors such as the aging population, the increasing prevalence of chronic diseases, and the development of new technologies.",
            "banner_image": "https://stocknews.com/wp-content/uploads/2022/05/shutterstock_245531419-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.256519,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "APG",
                    "relevance_score": "0.029363",
                    "ticker_sentiment_score": "0.16457",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.259573",
                    "ticker_sentiment_score": "0.290598",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.2872",
                    "ticker_sentiment_score": "0.277546",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.231608",
                    "ticker_sentiment_score": "0.193906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.029363",
                    "ticker_sentiment_score": "0.198349",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pent-up private Wegovy demand prompts UK availability concerns",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pent-up-private-wegovy-demand-prompts-uk-availability-concerns-2023-09-04/",
            "time_published": "20230904T174200",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "[1/3] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/JHTDYR7P4NPVFCN4MBVSNYGO6E.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.064193,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AIVAF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.110217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.117203",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy weight loss drug launches in the UK",
            "url": "https://www.cnbc.com/2023/09/04/novo-nordisks-wegovy-weight-loss-drug-launches-in-the-uk.html",
            "time_published": "20230904T122828",
            "authors": [
                "Karen Gilchrist"
            ],
            "summary": "Novo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug's rollout in Europe despite ongoing supply constraints.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107215515-Clean_Thumb.png?v=1680500866&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.243932,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AIVAF",
                    "relevance_score": "0.086245",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.33514",
                    "ticker_sentiment_score": "0.28516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/09/04/2736672/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20230904T121200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 4 September 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.125472,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.101174",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Factbox: Launches of Novo Nordisk's weight-loss drug Wegovy",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/launches-novo-nordisks-weight-loss-drug-wegovy-2023-09-04/",
            "time_published": "20230904T110833",
            "authors": [
                "Reuters"
            ],
            "summary": "Factbox: Launches of Novo Nordisk's weight-loss drug ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QTDKE2TN3JOLDFV25OA6NY4X54.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.075055,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALIZF",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "-0.144699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak",
            "url": "https://www.forbes.com/sites/roberthart/2023/09/04/weight-loss-drug-wegovy-launches-in-uk-as-shares-of-drugmaker-novo-nordisk-hit-new-peak/",
            "time_published": "20230904T101619",
            "authors": [
                "Robert Hart"
            ],
            "summary": "In August, Novo Nordisk's CEO said it could \"take quite some years\" for the company to meet soaring demand for the popular drug.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f5ae5ad15725c5c5b0157e/0x0.jpg?format=jpg&crop=8191,4606,x0,y428,safe&width=1200",
            "source": "Forbes",
            "category_within_source": "Business",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.185987,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112269",
                    "ticker_sentiment_score": "0.112415",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Maker Beats Bernard Arnault's LVMH As Europe's Most Valuable Firm With Stunning $423B Market Cap - LVMH  ( OTC:LVMUY ) , LVMH  ( OTC:LVMHF ) , Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/09/34200224/ozempic-maker-beats-bernard-arnaults-lvmh-as-europes-most-valuable-firm-with-stunning-423b-market",
            "time_published": "20230904T073706",
            "authors": [
                "Shanthi Rexaline"
            ],
            "summary": "Danish biopharma Novo Nordisk A/S NVO is reaping windfalls from its weight-loss drugs Ozempic and Wegovy, which continue to fly off the shelves. What Happened: In a significant move, Novo Nordisk's shares on the Copenhagen stock exchange closed Friday's session at 1,301.20 Danish Krone, marking a ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic_maker_Novo_Nordisk.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.389017,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47147",
                    "ticker_sentiment_score": "0.349433",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.332424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.332424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "European stocks rise on China optimism; Novo Nordisk scales new peak",
            "url": "https://www.reuters.com/markets/europe/european-stocks-rise-china-optimism-novo-nordisk-scales-new-peak-2023-09-04/",
            "time_published": "20230904T073200",
            "authors": [
                "Reuters"
            ],
            "summary": "European stocks rise on China optimism. Novo Nordisk scales new peak ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/7V5SZWDBMRLFFBLOKJGCYMH7HE.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.385781,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.345718",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.170658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VNNVF",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.345718",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk launches weight-loss drug Wegovy in UK",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-launches-weight-loss-drug-wegovy-uk-2023-09-04/",
            "time_published": "20230904T060409",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/HLLQH3RSGJPC3BY5YOQNZDHTAE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142264,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075874",
                    "ticker_sentiment_score": "-0.005127",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic maker overtakes LVMH as biggest European company",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-maker-overtakes-lvmh-as-biggest-european-company/3232119/",
            "time_published": "20230904T054503",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Danish drugmaker Novo Nordisk A/S on Friday surpassed French luxury powerhouse LVMH to become Europe's most valuable company, buoyed by demand for its blockbuster obesity medicines. Novo shares rose 2.1% in Copenhagen, boosting its market capitalization to the equivalent of almost $425 billion.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/vitamin-d-gdea28de0f_640.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.202737,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.118152",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.124992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.118152",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.276802",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.091319",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Disruptive Power of Weight Loss Drugs Is Being Felt Beyond Pharma",
            "url": "https://www.nytimes.com/2023/09/02/business/dealbook/the-disruptive-power-of-weight-loss-drugs-is-being-felt-beyond-pharma.html",
            "time_published": "20230902T120002",
            "authors": [
                "Vivienne Walt",
                "Lauren Hirsch"
            ],
            "summary": "Retailers, the makers of foods marketed for weight loss, and other types of companies could see knock-on effects from the rise of diabetes and weight loss drugs like Ozempic.",
            "banner_image": "https://static01.nyt.com/images/2023/09/02/business/02DB-OZEMPIC/02DB-OZEMPIC-articleLarge.jpg?quality=75&auto=webp&disable=upscale",
            "source": "New York Times",
            "category_within_source": "Dealbook",
            "source_domain": "www.nytimes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": -0.002422,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "-0.051896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMPL",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.017823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLF",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.076529",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RAD",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.085774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.109729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MED",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.099729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PPRUF",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.131728",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.085774",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Disruptive Power of Weight Loss Drugs Is Being Felt Beyond Pharma",
            "url": "https://www.nytimes.com/2023/09/02/business/dealbook/weight-loss-drugs-diet-companies-ozempic.html",
            "time_published": "20230902T120002",
            "authors": [
                "Vivienne Walt",
                "Lauren Hirsch"
            ],
            "summary": "Retailers, the makers of foods marketed for weight loss, and other types of companies could see knock-on effects from the rise of diabetes and weight loss drugs like Ozempic.",
            "banner_image": "https://static01.nyt.com/images/2023/09/02/business/02DB-OZEMPIC/02DB-OZEMPIC-articleLarge.jpg?quality=75&auto=webp&disable=upscale",
            "source": "New York Times",
            "category_within_source": "Dealbook",
            "source_domain": "www.nytimes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": -0.002422,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "-0.051896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMPL",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.017823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLF",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.076529",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RAD",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.085774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.109729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MED",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.099729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PPRUF",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.131728",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.024297",
                    "ticker_sentiment_score": "0.085774",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could CVS Make a Copy of Ozempic?",
            "url": "https://www.fool.com/investing/2023/09/02/could-cvs-make-a-copy-of-ozempic/",
            "time_published": "20230902T113500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Given its new biosimilars unit, copying Ozempic is more likely than it sounds.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745806%2Fsocial-security-benefits-application-retirement-income-getty.jpg&op=resize&h=340",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.09264,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.454714",
                    "ticker_sentiment_score": "0.104692",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.124992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.045099",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jeff Bezos Vs. Elon Musk Space Contract Lawsuit, Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations, Tesla Rival XPeng's August Deliveries Zooms 43% - Booking Holdings  ( NASDAQ:BKNG ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/news/23/09/34172689/jeff-bezos-vs-elon-musk-space-contract-lawsuit-novo-nordisks-famed-drug-ozempic-could-be-next-conten",
            "time_published": "20230901T140551",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "An institutional investor prosecuted Amazon.Com Inc AMZN and its board, including Jeff Bezos, over launch contracts awarded to Bezos' space company, Blue Origin.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/01/blue_origins_new_glenn_launch_29350547990_0.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.209544,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.259605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.202808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.033454",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.206499",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.166743",
                    "ticker_sentiment_score": "0.14251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "-0.098063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.245825",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.145158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.181682",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.181682",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Next For DexCom Stock After A 17% Fall In A Month?",
            "url": "https://www.forbes.com/sites/greatspeculations/2023/09/01/whats-next-for-dexcom-stock-after-a-17-fall-in-a-month/",
            "time_published": "20230901T130042",
            "authors": [
                "Trefis Team"
            ],
            "summary": "DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f172bbc826a8a8881e8144/0x0.jpg?format=jpg&width=1200",
            "source": "Forbes",
            "category_within_source": "Markets",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.17935,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.830107",
                    "ticker_sentiment_score": "0.301318",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "-0.055025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Famed Drug Ozempic Could Be Contender For Medicare Negotiations: What Price Negotiations Mean For Diabetes Patients - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/09/34167088/novo-nordisks-famed-drug-ozempic-could-be-a-contender-for-medicare-negotiations",
            "time_published": "20230901T121319",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S's NVO Ozempic, the highly sought-after diabetes treatment, may soon enter the realm of price negotiations between drug manufacturers and Medicare. Ozempic is poised to become eligible for negotiations when the next batch of drugs is chosen in 2025, leading to price adjustments ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/01/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.14328,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.312158",
                    "ticker_sentiment_score": "0.116942",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk briefly overtakes LVMH as Europe's most valuable company",
            "url": "https://www.reuters.com/markets/europe/drugmaker-novo-nordisk-briefly-overtakes-lvmh-europes-most-valuable-company-2023-09-01/",
            "time_published": "20230901T104600",
            "authors": [
                "Danilo Masoni",
                "Lucy Raitano"
            ],
            "summary": "A coffee machine featuring Novo Nordisk logo is seen at the company headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/NOVO%20NORDISK-LVMH/VALUATION/jnvwwxmgjvw/1693561257598.png",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.203241,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "-0.041962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CFRHF",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "-0.117609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.051719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.2589",
                    "ticker_sentiment_score": "0.169676",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Reasons ResMed's CEO Isn't Worried About Ozempic or Wegovy",
            "url": "https://www.fool.com/investing/2023/09/01/3-reasons-resmeds-ceo-isnt-worried-about-ozempic-o/",
            "time_published": "20230901T102100",
            "authors": [
                "Jason Hawthorne"
            ],
            "summary": "Mick Farrell might be kidding himself about the degree to which the popular weight-loss drugs will impact his company.",
            "banner_image": "https://media.ycharts.com/charts/e7a9f7fa78ee5e626d29a1324aae27e9.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.002418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "RMD",
                    "relevance_score": "0.294345",
                    "ticker_sentiment_score": "-0.033133",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "-0.050481",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic could be the next target of Medicare drug price negotiations - here's why",
            "url": "https://www.cnbc.com/2023/08/31/ozempic-could-face-medicare-drug-price-negotiations-next.html",
            "time_published": "20230831T154058",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107293899-16934103301693410325-30978481485-1080pnbcnews.jpg?v=1693410803&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.095253,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.042196",
                    "ticker_sentiment_score": "0.013729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.042196",
                    "ticker_sentiment_score": "0.283061",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.042196",
                    "ticker_sentiment_score": "0.111534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084275",
                    "ticker_sentiment_score": "0.090383",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "US senators push drugmakers for details on low-cost insulin programs",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-senators-push-drugmakers-details-low-cost-insulin-programs-2023-08-31/",
            "time_published": "20230831T110300",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "[1/3] Boxes of the drug NovoLog, made by Novo Nordisk Pharmaceutical, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZYZVP7YTABMHRNRZWMXHTOWL3E.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.021303,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.219809",
                    "ticker_sentiment_score": "-0.06382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.219809",
                    "ticker_sentiment_score": "0.01856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.219809",
                    "ticker_sentiment_score": "-0.060927",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Denmark lifts economic growth forecast due to strong pharma exports",
            "url": "https://www.reuters.com/markets/europe/denmark-lifts-economic-growth-forecast-due-strong-pharma-exports-2023-08-31/",
            "time_published": "20230831T104600",
            "authors": [
                "Reuters"
            ],
            "summary": "COPENHAGEN, Aug 31 ( Reuters ) - The Danish government on Thursday lifted the country's economic growth forecast for 2023 due to higher-than-expected employment and the continued growth of the Danish pharmaceutical industry led by drugmaker Novo Nordisk ( NOVOb.CO ) .",
            "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=155",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.22749,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.540067",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "European Energy A/S: A record second quarter",
            "url": "https://www.globenewswire.com/news-release/2023/08/31/2734953/0/en/European-Energy-A-S-A-record-second-quarter.html",
            "time_published": "20230831T081700",
            "authors": [
                "European Energy A/S"
            ],
            "summary": "Company announcement ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b19b7d31-01b9-4746-995f-68d10a003c66",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.191145,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.117486",
                    "ticker_sentiment_score": "0.095331",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}